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ABSTRACT

Specht, Aaron James. Ph.D., Purdue University, August 2016. X-ray Fluorescence for
Quantification of Lead and Strontium In Vivo. Major Professor: Linda H. Nie.

Lead (Pb) is a toxicant well known for its effects on almost every organ system in the
body. Pb use in industry has declined since removal of Pb from gasoline, but many
developing countries still have significant use of Pb. Exposure to Pb has been linked with
diseases causing neurodegeneration and thus have lasting effects long after the initial
exposure. Another metal, strontium (Sr), has been linked with bone disease in particular
situations and shown to have uses in treating osteoporosis as a supplement. However,
there are no studies of the effects of Sr using a meaningful biomarker. The most
commonly used biomarkers for Pb and Sr exposures are blood Pb and Sr; however, blood
tests are unable to identify long-term exposure levels due to the short half-life of these
metals in blood. Bone stores of Pb and Sr have a half-life of years to decades and serve as
a biomarker of long-term exposure. X-ray fluorescence has been used to measure bone Pb
and Sr. However, current systems have limitations with radioisotope sources, bulky
equipment, and long measurement times. A portable XRF device capable of measurement
of bone Pb and Sr, overcomes the limitation of the current systems and has been
developed in this work. The detection limit of the portable XRF for bone Pb and Sr was
found to be 11 ppm and 5 ppm respectively at 5 mm of skin thickness. The portable XRF

xiv
will have limitations of measurement based on an individual’s skin thickness. The device
was calibrated using standard phantoms and validated with in-lab samples, which
demonstrated good agreement between KXRF and portable XRF measurements with
strong correlations between goat bone, cadaver bone, and phantom measurements. In a
population study of Pb poisoned children the portable XRF was further validated and a
significant correlation between KXRF measured bone Pb and portable XRF measured
bone Pb was identified; however, the device had limitations based on anatomical
differences unaccounted for in children from our calibration. Adaptations of our
calibration to account for the differences in children’s bone can be used to further
improve on the results we obtained. Pb biokinetics was studied in these children, and the
blood Pb half-life in the children was calculated to be about 10 days, which is much short
than the 30 day half-life identified for adults. Bone Sr was measured in these children and
a significant correlation with age was identified, indicating the Sr accumulates in bone. A
novel high-energy x-ray tube based KXRF measurement system was tested for its
feasibility of in vivo measurement of metals in bone using Monte Carlo (MC) simulation.
The novel system shows a combination of the advantages of the portable XRF with a
smaller scale device, x-ray tube source, and room temperature detector, as well as the
advantages of the KXRF of minimal soft tissue signal degradation with more
applicability to a wider range of populations. This device, with an optimized x-ray tube
and uranium target of 0.056 mm, was found to have a detection limit for bone Pb
measurement of about 3.6 ppm and could be adapted for measurements of multiple
metals.

1

CHAPTER 1. INTRODUCTION

1.1

Pb and Sr Toxicity

Pb has presented a perseverant problem to environmental health despite our control
standards and continues to especially affect many communities in developing countries.
Pb is a toxicant that affects many part of the human body. Pb exposure occurs via oral
cavity, inhalation, or dermal exposures, but dermal exposures are much less efficient. The
absorption of Pb depends on the age of the individual with children absorbing 5-10 times
more Pb from an oral dose than an average adult would. In adults about 94% of the Pb
burden will accumulate in the bones, whereas children will only reflect about 73% of
their Pb burden in bone [1]. Blood Pb is primarily in the red blood cells. Pb can act
similarly to calcium in many interactions in the body, which is why it is so easily stored
in bone. Pb acts primarily as an oxidative stressor to cause changes in organ systems.
Pb replaces calcium in many interactions in the body, and thus can affect nearly
every system. Pb exposure has been linked to many severe diseases and health risks
including cardiovascular disease, neurodegenerative disease, and even mortality[2-4]. Pb
has many adverse health effects in the body primarily affecting the central nervous
system [5, 6]. Neurodegenerative disease is of particular concern, as millions of adults
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with Pb exposure from leaded gasoline are aging and will be impacted by Pb associated
neurodegenerative disease in the coming years. The population associated with this
exposure is about 25 million people with effects lasting until the year 2050 [4]. Low-level
Pb exposures have been linked to cognitive effects in children [5, 6]. This is of
importance as well since these exposures can be obtained environmentally. Occupational
exposures are widespread in industry and more proper protections need to be in place to
ensure the safety of workers. A study from the CDC showed that over 11,000 workers in
the US were still exposed to dangerous levels of Pb with blood Pb values greater than 40
µg/dl, and almost 3,000 of those workers have had those blood Pb levels consistently for
multiple years [7]. The protections put in place for occupational workers are apparently
lacking as these high blood Pb levels persist. With its ranging effects over the body, even
at environmental exposure levels, persistent occupational exposure, and association with
long-term neuro-degeneration, bone Pb is a primary target for in vivo XRF technology,
which needs to be expanded for future identification of long-term chronic exposure and
associated health risk.
Pb is used in many different manufacturing and production environments. Pb has
properties that make it versatile for use in many different industries and is still used in
electronics, battery manufacturing, Pb alloy bearings, ammunition, and many other
applications. Most of the Pb consumption in the US comes from its use in batteries. In
developing countries Pb use is not as strictly enforced and Pb is used in things such as
gasoline and insecticides. Leaded gasoline is still used as an aviation fuel for particular
planes world-wide and releases over 100 tons of Pb each year [8].
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Sr may have beneficial and negative effects primarily on bone with exposures
being commonplace for most populations. XRF has been used in the study of many
metals including Pb for many years [9, 10].The documented health effects of Sr over
exposure are limited to changes in the bone. In a study where children ingested food
grown in soil with high levels of Sr there was a significant effect on developing bones of
the children leading to rickets in the children [11]. The subjects in this study also had a
lack of vitamin D and protein in their diets, which likely increased Sr metabolism and the
effects observed in the over-exposed population. Sr is known to act similarly to calcium
with 99% of the Sr in the body accumulating in the bone [12, 13]. However, beyond
effects in bone, other adverse health effects have not been studied for Sr alone.
Sr related health effects from over-exposure generally occur in specific
populations with confounding issues such as diet. Everyone is exposed to some levels of
Sr from food consumption and aerosols. Sr in soil and uptake in plants accounts for the
majority of Sr exposures worldwide and high levels of Sr in soil are common. Sr is a
naturally occurring element in the earth’s crust and oceans.
Sr has been shown to be beneficial for many people suffering from osteoporosis
[14, 15]. Studies showed that using a dose of 2 grams per day of Sr ranelate lowered the
incidence of non-vertebral fractures in post-menopausal women [15, 16]. This again
results from is similarities with calcium in the body, allowing Sr to replace calcium in
bone and strengthen the bone structure. Osteoporotic fractures account for 2.8 million
disability-adjusted life years in the Americas and Europe [17]. Thus Sr supplementation
as a preventative care measure could potentially help thousands of people; however,
proper studies of the effects of Sr are needed to ensure safety in these treatments.
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1.2

1.2.1

Biomarkers of Pb and Sr Exposure

Traditional Methods of Pb Exposure Assessment

The traditional biomarker for Pb exposure is blood Pb. Other biomarkers for Pb exposure
are bone, urine, plasma, and hair. Hair and finger prick blood Pb samples are prone to
contamination, and plasma levels are difficult to measure as the concentrations are
generally near the detection limit of the measurement instruments. Urine Pb is an
estimation of recent exposure levels and can vary based on volume of urine [18].
Biomarkers are generally chosen to reflect certain biological responses or total body
burden of the toxicant. In that sense, blood Pb is an appropriate measure of a persons
current exposure levels and potential health risk. The limitations of blood Pb are evident
when we look at whole body Pb burden and long-term health effects. Blood Pb only
reflects less than 2% of the total body Pb burden with the majority of Pb accumulating in
bone [19]. The half-life of Pb in blood is about 30 days [1]. This has implications in the
variability of blood Pb over a short period of time. It is possible for a blood Pb level to
change fairly drastically over the course of weeks. Blood Pb has a positive response with
exposure, but this relationship too can be less clear, as different ages and diet in subjects
can drastically change uptake of Pb in the body [20]. Blood Pb has the further
complication of analysis using inductively coupled plasma mass spectrometry (ICP-MS)
and atomic absorption spectrometry (AAS). These processes require a significant time
investment in taking and analyzing each sample, while maintaining a Pb free
environment.
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1.2.2

Traditional Methods of Sr Exposure Assessment

Sr exposure can be monitored a number of different ways. Similarly to Pb, Sr can be
monitored using a blood sample; however this likely reflects the acute exposure. This is
done by simply taking a blood sample and analyzing it using a detection system such as
AAS or ICP-MS. Similarly, urine, hair, and bone and be studied using a tissue sample
and AAS or ICP-MS. Urine, hair, and blood have less relevance to tracking of exposure
because of the accumulation of Sr body burden primarily being in bone. Since Sr
deposition occurs primarily in the bone, bone biopsy has been used to determine Sr
exposure, primarily in studies determining efficacy for treatment of osteoporosis [21].
Bone biopsy is difficult and painful procedure for patients and is generally avoided. A
device using dual photon absorptiometry (DPA) has been used to estimate levels of Sr in
bone [22]. This device uses two radioisotopes, which complicates the licensing
procedures, requires the submersion of the subject’s measurement site in water, and a 10minute measurement time. It also produces results in a measure of percentage Sr, which
is difficult unit for further comparisons to other biomarkers of exposure.

1.2.3

Bone Pb and Sr as a Biomarker

Bone has many advantages over blood biomarkers, but also has some limitations. Bone
Pb better reflects exposure, especially a cumulative exposure. It has a long half-life of
between 10-30 years, and accounts for between 70-90% of the total body Pb burden
depending on the age of the subject [1, 19]. The same can be assumed to be similar for Sr
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since 99% of Sr accumulates in bone [12, 13]. This long half-life has been used to better
illuminate health effects of Pb with delayed symptoms. Bone Pb and Sr is traditionally
measured through a KXRF bone measurement device. Bone Pb and Sr could also be
obtained through a bone biopsy; however, as mentioned previously this is a painful
procedure that would not likely be done multiple times. KXRF measured bone Pb and Sr
measurements have the advantage of being an assessment of cumulative exposure and the
measurements can be taken in vivo.

1.3

X-ray Fluorescence (XRF)

1.3.1 Principles of X-ray Fluorescence

XRF is a process that can be used to quantify elements in a particular sample using
radiation. An incoming radioactive source, which is usually photons, interacts with the
sample by means of the photoelectric effect transferring the photon energy to an electron.
This will eject an inner shell electron as long as the photon energy is greater than the
binding energy of the electron orbital, which typically is from the K or L shell for XRF.
An electron from an outer orbital within the atom then de-excited into the orbital the
electron was ejected and releases the difference in energy between the two orbitals, which
has an energy specific to an individual element. That energy release is the characteristic
x-rays, and is collected by a detector.
Each step in the process is governed by specific calculated probabilities. The
initial photoelectric interaction depends on the ability of the source radiation to penetrate
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to the sample without significant attenuation, and interact by photoelectric absorption
rather than either Compton scatter or Rayleigh (coherent) scatter. After a photoelectric
interaction, the characteristic yield will determine the probability of a particular energy
line being represented from the element. Lastly, there is the probability of the isotropic
characteristic x-ray to be produced in the direction of our detector and the absorption of
the x-ray in the detector itself. These are all well studied physics interactions and easily
calculated events, which justifies the ability to use Monte Carlo simulation methods to
test many of these processes.
Beyond the physics, the calibration procedures for XRF are standard and
important to the understanding of the process itself. The interaction probabilities will all
increase linearly with increasing amount of a particular element. Thus, a linear
relationship between the events or counts in the detector for a particular characteristic xray will relate to an increase of similar magnitude of concentration of that particular
element in the measured sample. Through calibration using samples of known levels of a
particular element in similar structural matrices to a test sample, we can determine the
concentrations associated with each level of counts.
The detectors used for XRF also need to be specifically chosen for each purpose.
Detectors with materials able to produce higher energy resolution are most valuable for
use in XRF, since each element has characteristic energies. A high energy resolution
allows us to discern more easily between a particular element’s energy and background
or noise surrounding. Each element observed in a sample will be represented in the
energy spectrum with a Gaussian peak centered at the characteristic energy. The width of
the Gaussian peak is determine by the resolution of the detector and will determine the
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ability to resolve the characteristic x-rays from background and other characteristic peaks
of energy close to the peak of interest.
XRF technology is unique in its ability to quantify exposure levels in vivo. The
tissue type observed through these techniques can be chosen specifically to aid in
identifying health effects from exposure. For Pb, bone is used as the measurement site for
its previously mentioned biological half-life of 10 to 30 years, and its accumulation of up
to about 90% of the total body Pb burden [1]. Utilizing the physics principles and
optimizing detector and calibration procedures we are able to do measurements of many
elements in vivo.

1.3.2

In Vivo X-ray Fluorescence Systems for Bone Pb and Sr Measurements

The first in vivo measurement done using XRF was monitoring iodine in thyroid in 1968
[23]. The first bone Pb measurement using KXRF was completed in 1976 by Ahlgren et
al. [24]. These methods used a Co-57 source and were able to be optimized to the Cd-109
source with a HPGe detector in 1985 by Somervaille et al. [25]. This method was further
optimized by increasing the detector size from 16 mm to 51 mm diameter increasing the
acquired signal greatly [26]. The device by Gordon et al. is the typical instrument found
in most labs. One final iteration of improvements led to the design of the clover-leaf
KXRF measurement system, which has four 16mm HPGe detectors and uses a stronger
source than the previous iteration, to lower the minimum detectable limit even more [27,
28]. Bone Sr has been measured more recently using similar equipment as bone Pb with
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HPGe detectors with Cd-109 source in a 90-degree and 180-degree geometry and extra
shielding around the source and detectors [10].
Current KXRF technology has limitations based on the instrumentation, which
restricts the populations available for measurement. Current KXRF systems utilize a Cd109 radioisotope and high-purity germanium (HPGe) detector system to perform bone Pb
measurements. Radioisotopes in general require site-specific licensing procedures that
limit the facilities available for using the system. Thus, even if the system is transported
elsewhere, the site needs to go through the licensing procedure with the NRC to approve
use of the radioisotope. Normally, each site would then buy a source as well, which also
is problematic, as there are few sellers of the source. Then, the site would need a health
physics or radiation safety officer willing to go through the licensing process and perform
annual inspections on the source.
Another pitfall of the KXRF measurement systems is the size. The HPGe
detectors require cooling using liquid nitrogen, which drastically increases the size and
weight of the system, making transportation much more difficult and requiring dedicated
space and cooling for the system. The site for measurements needs to have access to
liquid nitrogen every week to refill the Dewar of the detector. These are all costs that are
recurring and for some sites without access to liquid nitrogen, delivery of liquid nitrogen
weekly is going to be necessary for the duration of the detectors use.
Finally, the measurement itself requires 30 minutes. For large populations, this
can be a significant time investment for research personnel. 30 minutes can be a long
time for a measurement of certain populations, especially in children or adults with
Alzheimer’s or dementia who may have difficulty sitting still.
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Since KXRF has so many limitations, alternatives were explored using L-shell
XRF (LXRF). LXRF for bone Pb measurement was first developed in 1983 using an I125 source [29]. An x-ray tube source utilizing polarized x-rays was then developed for
LXRF measurement of Pb in bone [30, 31]. Finally an x-ray tube source with secondary
target was developed for LXRF measurements [32-34]. Using an x-ray tube source
eliminated the licensing restrictions of the KXRF system; however, these methods all
found variability in soft-tissue thickness to be a significant problem and did not have
proper methods to correct for this in their calibrations. Finally, the development of the
work described in this thesis identified a calibration with correction for soft-tissue
thickness to allow for measurements using our LXRF system in vivo [35, 36].
The previous LXRF technologies had limitations primarily with calibration to
overcome varying soft tissue thickness over bone. In addition to this, geometry factors
play a much larger role with LXRF than KXRF. KXRF uses a high-energy source that
will penetrate further into the bone and the characteristic x-rays produced isotropically
will be of high energy as well and able to exit the bone into the detector without
significant attenuation from surrounding soft tissue structures. LXRF using the much
lower energy has an attenuation factor about 20 times that of the KXRF energies. This
represents only millimeters of penetration or measurement depth for the characteristic xrays released in the material. Combine this with the fact that these LXRF devices are
utilizing x-ray tubes, which will have a small beam size limiting the area of irradiation to
a specific location. This is where I believe the studies done by Todd had their
shortcomings, and likely has contributions to the other previous LXRF devices as well
[32-34]. The geometry is so sensitive to the fact that the detector has to be placed
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precisely where the maximum number of characteristic x-rays will be able to escape, but
most importantly it needs to be consistently in the exact same geometry for every
measurement. Even a 1.5 mm difference in source detector geometry would represent a
change in the signal by a factor of 2. This is evident in Todd’s studies, which revealed a
reproducibility that was unacceptable for measurement [32]. In the work described here,
we have correctly isolated the geometry and have the detector and source in a stable
reproducible setup allowing us to overcome previous device limitations.
The soft tissue attenuation presented another significant problem for LXRF
measurements. Measurements of soft tissue were needed along with the LXRF
measurements in order to properly account for the attenuation. This step in itself added
uncertainty to the measurement. A study by Rosen et al. demonstrated this in a population
study of children and was able to successfully measure bone Pb using LXRF with
ultrasound measurements [37]. The need for a proper calibration including soft tissue
thickness is evident by these methods, which limited the detection limit, increased
uncertainty, and required extraneous instrumentation in studies using LXRF bone Pb
measurements. The work presented here will detail specific calibration procedures
utilized with our developed system that allows for appropriate correction for soft-tissue
thickness and overcomes the limitations of previous LXRF measurement systems.
To address the disadvantages of KXRF and overcome the limitations of LXRF
this thesis will present the development of a novel portable LXRF device and a portable
KXRF device with advantages using an x-ray tube source, detector without liquid
nitrogen cooling, and significantly reduced measurement times.
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1.4

Overall Goals and Specific Aims

The goals in my project were to develop and validate use of a portable XRF device for in
vivo measurement of bone Pb and bone Sr, and to determine the feasibility of a highenergy x-ray tube XRF device for use with in vivo applications. The portable XRF can
then be used for monitoring cumulative Pb exposure levels in populations to assess the
health effects associated with exposure. To achieve the overall objective four specific
aims for this doctoral work were accomplished:
Aim 1: Calibrate and validate the portable XRF system for in vivo Pb
quantification and improve upon previous XRF technology. We developed and validated
a portable system to quantify Pb concentration in tibia bones. We used a portable x-ray
tube system from Thermo Fisher generally used for environmental and industry samples,
optimized the device settings for use in vivo, developed calibration methods, and
validated the device with phantoms, goat bone, and cadaver bone. The work for this aim
was published in a paper by Specht et al in 2014 [38].
Aim 2: Validate the portable XRF bone Pb measurement system using a
comparison with KXRF data in a Pb poisoned children study. We measured tibia Pb in a
population study of Pb poisoned children with both KXRF and portable XRF. We
quantified Pb concentrations in their tibia bones with the portable XRF and KXRF
systems and compared the results. We identified differences in Pb biokinetics in children.
The work for this aim was published in a paper by Specht et al in 2016 [36].
Aim 3: Validate the portable XRF system for in vivo bone Sr quantification.
Using the same system as for Pb, we developed and validated a system to quantify Sr in
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tibia bone. We created phantoms for use in calibration of Sr with the portable device. We
used optimized settings and calibration methods from Pb. We did an analysis for Sr with
the data collected in the Pb poisoned children population study, and identified sex
differences of Sr accumulation with age.
Aim 4: Develop a novel XRF device for quantifying metals. We developed a
higher energy x-ray tube system for use with quantifying metals using MCNP. We
simulated the design of a novel higher energy XRF system. We identified optimized
settings of the x-ray tube and detector to maintain advantages of previous systems with a
low detection limit.

1.5

Significance

Metal exposure has increased dramatically through the years with increased development
of industry, agriculture, and manufacturing. Pb has been a centerpiece for metal exposure
with its numerous adverse health effects especially within the central nervous system [39].
Pb exposures have decreased with the removal of Pb from gasoline. However, Pb
exposure and toxicity remains an important public health issue as: low level Pb exposure
has been increasingly correlated with adverse health effects[2, 3, 40-43], high exposures
remain commonplace in occupational workers [7], and significant internal exposure
persists for individuals from the leaded gasoline era [4]. For these exposed population,
we need to identify cumulative effects of Pb to determine whether current public health
and treatment initiatives are correctly focused.
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Traditionally, blood Pb is used as a biomarker to determine Pb exposures, but
blood Pb has a half-life of 30 days; bone Pb with its half-life of years to decades better
reflects lifetime exposure levels [1, 44] and for many, particularly chronic, conditions has
proven to be a much more relevant biomarker. Current Cd-109 KXRF systems have been
used to study cumulative Pb exposure for over two decades, but it requires radioisotopes,
long acquisition times, and a large amount of space [9, 45]. Radioisotopes require
extensive licensing procedures from each site with an active system and significant
maintenance from health physicists. This and other space limitations have severely
restricted the use of this approach in research with only a few research groups having
conducted such studies. In this thesis we use a portable XRF device to overcome the
disadvantages in portability and measurement time. This device was validated alongside
KXRF bone Pb measurement and with these measurements of bone and blood Pb we
investigated the biokinetics of Pb in children.
This project is significant because: it will develop a system for Pb measurement
with improved portability and without radioisotope restrictions. Development of this
system will allow for measurement of populations previously inaccessible by traditional
KXRF systems due to radioisotope restrictions or portability requirements, which will
help identify at risk populations for public health initiatives, and make this line of
research available to a far wider research community than currently, and with expanded
development be applicable for measurement of other metals in other tissues.
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1.6

Structure of This Dissertation

The structure of this dissertation is organized by the following order: Chapter one
consists of introduction and background information; chapter 2 addresses the portable
XRF optimization and validation with in lab samples with study results from my
publication [38]; chapter 3 addresses the Pb poisoned children population study
biokinetics and validation findings with study results from my publication [36]; chapter 4
focuses on the calibration and validation for bone Sr measurements with the portable
XRF and population study results; chapter 5 focuses on the development of a novel XRF
device for Pb quantification with simulation results; chapter 6 has an overall summary of
the studies and future directions for further study.
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CHAPTER 2. SIMULATION, OPTIMIZATION, AND VALIDATION OF PORTABLE
XRF FOR BONE PB QUANTIFICATION

2.1

Introduction

The portable XRF offers many advantages over previous bone Pb measurement
technologies. Optimization of the portable XRF needs to be completed to determine the
settings that properly fit with the technology to get the lowest limit of detection for in
vivo measurements. The minimum detection limit (MDL) will define the usefulness of
the technology and gauge its ability to measure the general population. Along with
system optimization, optimization of our calibration procedures using different
approaches will allow us to determine the spectral features and analysis manipulations
that can be done to further minimize our detection limit. Previous technologies have the
advantage of a system, calibration, and analysis process that has been tested and refined
for almost a decade. Calibration and optimization for the portable XRF will require a
different approach to previous technologies, as soft tissue thickness needs to be
accounted for, preferably using spectral features and physics theory. With a proper
calibration, validation is an easier process that can be used to help explore the limitations
and potential problems of the device itself or the calibration used.
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When exploring our potential calibration methods we revisited the physics of
XRF and the anatomical make-up of an in vivo measurement. The energy of the portable
XRF limited us to the probable interactions in a sample of Rayleigh scattering, Compton
scattering, and photoelectric effect, which together determine the total attenuation as seen
in Figure 2.1 from NIST [46].

Figure 2.1 Plot of total attenuation cross section for cortical bone from NIST [46].

The photoelectric effect dominates at lower energies with a slowly increasing Compton
scattering probability as the energy increases. As mentioned previously the photoelectric
interaction will generate all of our signal from x-ray fluorescence measurements and
Compton scattering events will lead to an increase in background around that signal.
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Along with that the cross-sections will change depending on the material composition of
the bone or soft tissue. At the energies useful for XRF, the photoelectric cross section
changes as such with energy and atomic number,

!!" ∝ !

!!
!!

, where !!" is the cross section, Z is effective atomic number of the material, ! is the
density of the material, and E is the energy. The Compton scattering cross section at the
energies for XRF typically have only one dependency, which is a linear relation with
density. Our calibration methods will attempt to use some of these relations to identify
which interactions have the most relevance to overcome the many changing variables that
encompass in vivo measurements. Finally, the calibration can then be tested using in lab
samples to further validate the device, optimization, and calibration.

2.2

2.2.1

Materials and Methods

Portable XRF Bone Pb Measurement System

The portable XRF devices used in this work were from Thermo Fischer Scientific Inc.
(XL3t and XL3t GOLDD+, Billerica, MA). Traditionally these devices are used to
quantify elements in soil and rock samples for mining purposes. Advances to the detector
and geometry allowed us to apply these devices for in vivo measurements. The devices
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both have a power output of 2 watts, a 50 kV max x-ray tube voltage, with silver anode.
The XL3t is equipped with a Silicon (Si) PIN diode detector with 8 mm2 area, whereas
the XL3t GOLDD+ is equipped with a Si drift detector with 25 mm2 area. Both detectors
had thickness of 1 mm. This represents a 300% increase in size for the detector, which
will increase the characteristic x-ray signal collected by the detector. This does not equate
to a 300% decrease of the detection limit, because there is a gap between the detector and
the sample. The characteristic x-rays are produced isotropically, which makes the
increase of detector size limited by the gap combined with the amount of solid angle the
detector size covers, which will be much less than 300%. The company controls the
release of the exact specifications for these devices, but they claimed a better geometry to
further decrease detection limit was also introduced in the GOLDD+ device.
We can speculate on the changes between devices to decrease the detection limit
for different elements. In order to use geometry to decrease the detection limit a couple of
optimizations needed to take place. First, they could optimize the angle of the detector to
be perpendicular to any characteristic x-ray source, thus allowing for a greater coverage
of solid angle, for more signal collection. Second, they could minimize the distance
between the detector and sample to decrease the effect of the inverse square degradation
of signal and increase solid angle coverage. Both systems are quite compact, so it was
likely a combination of these optimizations, and possibly some changes to the angle of
the x-ray beam to accommodate the changes.
We performed an optimization of the device both for the x-ray settings and
filtration of the x-ray beam. The device had a set number of filters that we could apply to
the x-ray beam allowing us to change the energy spectrum of the emitting x-rays. For
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maximal output of characteristic x-rays you would ideally want to set the energy as close
to the binding energy of the element of interest as possible. Since this process is through
the photoelectric effect, the cross section will decrease with increasing energy, so being
right at the edge of the binding energy maximizes the amount of photoelectric
interactions. In the KXRF system they do this very well using 88.035 keV of Cd-109 for
the 88.01 keV binding energy of the Pb k-shell. However, with an x-ray tube this process
is more difficult, as x-ray tubes will produce a spectrum of energies. X-ray tubes can
have increased average energy using filtration of the x-ray beam.
Filtration of an x-ray beam is done using external filters after the target (anode)
and in the target itself. The x-ray beam in the portable XRF uses a transmission x-ray
tube, which produces the beam in the same direction as the electrons were accelerated.
This is contrary to traditional x-ray machines in the hospital, which use an angled anode
to produce a beam 900 from the original electron beam. A transmission x-ray tube
generally will have more filtration in the target from self-absorption events. Thus the xray beam has a higher average energy. The optimization of the target thickness in these
devices was done for many different elements and not just Pb and Sr, which we are
particularly interested in. Thus without the external filters the x-ray beam produced in
these devices was not very well optimized for our purposes.
For our optimization, we used measurements of phantoms and a calculation of the
minimum detection limit (MDL) as our standard for determining the optimized settings.
We discuss the MDL calculation in the results section of this chapter. We found the
optimized settings to be using 50 kV 40 µA and a filter of silver and iron with our
measurement time of 3 minutes. The dose of the device was estimated from previous
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TLD measurements taken at 50 kV 25 µA with the same filter. Since the only change was
to the current, the dose should scale proportionally to the increase in current, because
increases in current will just increase the output of the x-ray beam, and not the energy
spectrum of the x-ray beam. The entrance skin dose was then estimated to be 31mSv to a
1 cm2 area of skin [47]. We used 1 cm2 to be conservative in our estimates, but the NRC
standard is for a 10 cm2 area of skin for dose estimations, and the limit is 500 mSv to the
skin of the whole body or to the skin of any extremity for a radiation worker. The whole
body effective dose was then estimated similarly to be 3.6 µSv [47]. This can be
compared to the dose of a standard AP chest x-ray of about 100 µSv. The risk of this
radiation dose to any member of the public would be negligible.

2.2.2

KXRF Bone Pb Measurement System

In our study, we used the most advanced KXRF cloverleaf system discussed previously.
The cloverleaf KXRF bone Pb measurement system utilized four 16 mm HPGe detectors,
DSA-1000’s for signal processing, and used Genie 2k spectroscopy software for data
collection. The device has a previously measured detection limit of around 2-3 µg/g bone
mineral [27]. The system’s four detectors are placed around the Cd-109 radioisotope
source, and the system uses a 1800 geometry. The Cd-109 energy is 88.035 keV and the
binding energy for Pb is about 88.01 keV, which allows a special analysis method using
coherent scattering. Since the coherent scattering will reflect the interactions in the bone,
based primarily on effective atomic number of the materials, it can be used as a
normalization factor to determine the amount of bone mineral that was irradiated. This
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also allows us to determine the units in µg per gram bone mineral, which is more valuable
than a determination solely of parts per million, because it can be related back with more
biological significance.
The Cd-109 source usually starts at about 135 mCi and will decay over time with
its half-life of about 3 months. The source is placed in a holder with most of the point
source pointing forwards to few millimeter copper collimator to reduce dose from the
competing decay processes from the Cd-109, since the 88.035 keV gamma release only
represents ~3% of the branching ratio for the radioisotope decay scheme. With
decreasing source strength the integrity of each measurement in comparison to previous
can be maintained by decreasing the distance between the source and measurement site,
which can be monitored by using the dead time of the detector as an indicator.
The measurements were taken for 30 minutes, processed with the digital
electronics, and spectra analyzed using our in-house peak fitting software to calculate the
final Pb concentrations. The whole body effective radiation dose of each measurement
was assessed to be 0.26 µSv for adults and 10 µSv for children [48]. The Cd-109 source
has a more significant dose given to the bone marrow of subjects, which has a higher
tissue-weighting factor in children, so will result in a higher dose value.

2.2.3

Monte Carlo (MC) Simulation

MC simulation is a tool that uses a large number of probability calculations to determine
the impact of certain processes on systems. In our case, we have physics equations
determining the probability of interactions for each interaction based on energy and
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material. We can input a number of particles that are defined to go through those
interactions and based on the probabilities the MC simulation determines how they
interact. Finally, we can look at a particular outcome or interaction specifically to
compare with experimental result.
We used a standard software package from Los Alamos National Lab called
Monte Carlo N-Particle transport code (MCNP). This software has more updated low
energy interactions, which is needed for doing any validation with the portable XRF.
MCNP uses a simple input syntax, where the user defines objects using corresponding
intersections between different functions such as six planes intersecting to form a cube.
The user can then set each object to a material that can be specified using mass
percentages. Finally, the user can define a source, which can be electrons, photons, or
neutrons that then will produce particles of a particular energy or spectrum of energies to
interact with the objects.
MCNP allowed us to input the objects and geometry from the portable XRF
exactly, so that we could better understand the x-ray source produced in the system and
define calibration standards for our system to work with. Using the simulation we can
determine from physics interaction theory whether our methods and materials were
appropriate and if not how we should change them.

2.2.4

Phantom, Goat Bone, and Cadaver Bone Samples

In-lab samples were used in this study to verify the accuracy of our chosen calibration
method and to calibrate the device itself. Phantom materials made of plaster-of-Paris are
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commonly used for XRF bone measurement calibrations, so we used a set of phantoms
with known Pb doped concentrations at 0, 5, 10, 15, 20, 30, 50, 75, and 100 ppm for our
calibration. Since we knew soft tissue thickness would become an issue with the lower
energy portable XRF, we wanted our calibration to attempt to combat this, so we used
Lucite plates in increments of about 0.5 mm up to 6 mm in conjunction with our bone
phantoms to determine the affect of soft tissue on the measurements.
Goat bones were obtained from goats that orally ingested Pb of various levels. The
goat bones were grinded down and compacted into the form of small discs for
measurement and then placed in vacuum-sealed bags to prevent contamination. They had
concentrations of 0.2, 9.6, 16.1, and 31.4 ppm as measured by our KXRF bone Pb
measurement system. We used these along with the Lucite slabs to determine if the bone
matrix had any effect on our calibration method. We also used the Lucite slabs at 0, 1, 2,
3, 4, and 5 mm with the goat bones to determine the validity of our correction for soft
tissue thickness and the calibration method that correctly adjusted for it.
We had 10 cadaver bone samples with 3 having intact soft tissue thickness over the
tibia bone. They were also placed in vacuum-sealed bags to prevent contamination of the
bones and the portable XRF. The bones had varying Pb concentrations ranging between
3.6 and 23.1 ppm with most of the bones being around 20 ppm. We used these to further
verify the bone matrix equivalence to in vivo for our calibration and for reproducibility
measures of our portable XRF. We used Lucite slabs of 0, 1, 2, and 3 mm in conjunction
with the cadaver bones to determine the accuracy of measruements made with soft tissue
thickness for human bone.
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2.2.5

Calibration Methods for the Portable XRF

2.2.5.1 Traditional Peak Fitting

Traditional peak fitting is the standard way to calibrate a device for quantification using
calibration standards. We used Matlab for fitting of our spectra. We combined a Gaussian
peak fit for the Pb peaks with an exponential function to represent the background under
the peaks. We set the ranges for the variables in the fitting to values to reflect the
volatility of each variable. For example, the amplitude of the Gaussian was set between
±100, which reflected the counts for about 500 ppm. The background variables were
ranged through ±infinity, because they are more likely to change drastically for different
spectra. The peak location was set to be within one sigma of the energy of the
characteristic x-ray energy, and the width was determined using tests with the detector.
The Gaussian peak width was set to reflect the resolution of the detector for the
portable XRF. We did this using two methods 1) using a large peak from Sr measured
from our plaster-of-Paris phantom (~1000 ppm) to determine the resolution and then
converting that to the energy of the Pb peak regions, and 2) using the 100 ppm Pb
phantom to determine the width of the peak at the Pb regions. These two methods were in
agreement and we used a range of ±20% of the indicated width to account for variations
in background level and surrounding noise that may distort the width of the Gaussian
peak.
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Traditional peak fitting using this method worked well as long as the peak was
visible over the background and, as we will see later, had less influence from variables
from the in vivo situation. For measurements we did a soft tissue or Lucite correction for
these values by identifying the tissue thickness and determining signal degradation from
that particular thickness of tissue. For this we used a function both to identify soft tissue
thickness and to signal degradation of the ppm versus counts function as derived from the
traditional peak fitting calibration.

2.2.5.2 Background Subtraction

The background subtraction method was a unique calibration method identified to try to
combine the correction for soft tissue and traditional calibration line to quantify Pb signal.
We found that the background and the Compton scattering peak attributed to the Ag
characteristic x-rays from the x-ray tube target were well correlated. The physics
confirms this, as the characteristic Pb or other elemental x-rays will arise from
photoelectric interactions within the sample, and the other interactions will all lead to
background in the spectrum. Compton scattering is the primary interaction other than
photoelectric absorption, so the Compton scattering peak from the Ag x-rays is a
demonstration of the cross section for Compton scattering in that particular sample being
measured, and can then be used as a reflection of the background obtained in that
particular sample.
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For this calibration we would do measurements of the 0 ppm and 100 ppm
phantoms for 0, 1, 2, 3, 4, and 5mm of Lucite thickness. Lucite thickness was reflected in
the spectra using the Compton scattering peak from the Ag target x-ray. This would then
allow us to create functions to define the background from the 0 ppm phantom
measurements and how the background counts changes with increasing Compton
scattering counts. The function of background and Compton counts is in Figure 2.2 below.
Then we could similarly look at net counts of the Pb peak as it relates to Compton
scattering counts over increasing Lucite thickness, such as in Figure 2.3 below.
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Figure 2.2 Background counts under Pb L-alpha region versus Compton scattering counts
at varying thicknesses of Lucite.
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Figure 2.3 Net Pb L-alpha peak counts versus Compton scattering counts at varying
Lucite thicknesses.

The background function deviates more from the estimation at higher Lucite
thicknesses, which may be an indication of higher background levels arising from
interactions other than Compton scattering. Besides that deviation, the functions show
good agreement with high correlation values.

2.2.5.3 Bone Calibration

Bone calibration was tested to determine whether the bone matrix would have a greater
impact on the measurements. This method was the same as the background subtraction
method previously discussed; however, this method used the goat bone samples of 0.2
and 31.4 ppm instead of the 0 and 100 ppm phantoms respectively. Using this had the
advantage of using a bone matrix that would be very consistent with human bone and
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thus any changes in the spectra that would be because of the matrix would be reflected in
this substitution of phantoms.

2.2.5.4 Bone Adjustment

The final calibration method we explored tried to directly adjust each measurement for
the differences in effective atomic number and density of the sample. This was done by
correlating the Compton scattering peaks of the goat bone and phantom, as seen in Figure
2.4, so that any measurement done on normal bone could then have this function applied
to allow for use with a normal phantom calibration. This was done because bone
calibration seemed like a more reasonable approach to calibration, but had the great
disadvantage of having a low Pb concentration goat bone of 31.4 ppm to use in the
calibration process. This calibration method was supposed to correct for the bone matrix
without giving up the advantage of the higher concentration standards in the calibration
line.
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Figure 2.4 Goat bone versus phantom Compton scattering counts function.

2.3

2.3.1

Results

Portable XRF Spectrum

Figure 2.5 shows the resultant portable XRF spectrum from a measurement of an intact
human cadaver bone with 1.3 mm soft tissue. As shown in the spectrum the Compton
scattering peak comes from the x-ray tube silver characteristic x-rays undergoing
Compton scattering in our sample. This is the peak that we have correlated with
background and signal degradation from inverse square and attenuation using our
background subtraction method. It is also the peak that correlates well with soft tissue
thickness, so in a sample with more soft tissue, this peak will appear larger. The Pb peaks
at 10.5 keV and 12.6 keV are visible in this spectrum with only 1.3 mm of soft tissue
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thickness and 14.3 ppm of Pb. This spectrum demonstrates the difficulty in using
traditional peak fitting methods, since with more soft tissue, there will be more
background and the Pb peaks will become increasingly noisier.

Figure 2.5 Example portable XRF spectrum when measuring cadaver bone with
overlying soft tissue.

2.3.2

MC Validation of Phantom Materials

We used a MC simulation of the portable XRF itself to determine the validity of our
choices for phantom materials. This allowed us to test the measurement on a sample of
known soft tissue and bone elemental mass percentages, and then test it with our Lucite
and plaster-of-Paris phantom materials without changing any of the settings or geometry.
According to the simulation there was no significant changes between bone and soft
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tissue and plaster-of-Paris and Lucite. There were minimal spectral changes to the
Compton peak when changing between bone and plaster-of-Paris, but these were less
than a 5% change, which is about equal to the uncertainty from the simulation itself. This
result if true, would validate the use of the phantom material for our calibration, since we
would also be testing other calibration methods using materials more comparable to bone
matrix. Figure 2.6 shows the spectrum comparison between bone and phantom,
demonstrating their equivalence.
When testing the differences between Lucite and soft tissue, we used composition
information taken from NIST for soft tissue. We tested this using simulation at varying
thicknesses from 0, 1, 2, 3, 4, and 5 mm. Figure 2.7 shows the resultant differences
observed for the 5 mm values are about 20%. We attempted to verify this result using the
cadaver bone with intact soft tissue thickness in comparison to our Lucite plates, and
found the resultant spectrum shown in Figure 2.8 with better agreement than the
simulation led us to believe. This compares both plaster-of-Paris and Lucite to cadaver
bone with intact soft tissue thickness, which should be equivalent to the in vivo
measurements. The difference between these spectra was less than 5% as compared by
taking a ratio of above and below the Compton scattering energies.
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Figure 2.6 Bone and plaster-of-Paris bone phantom spectrum comparison.
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Figure 2.7 Comparison between the Compton scattering peak area for varying Lucite and
soft tissue thicknesses using simulation.
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Figure 2.8 Comparison of experimental phantom and Lucite to cadaver bone and intact
soft tissue thickness showing differences of <5%.

2.3.3

Soft Tissue and Compton Correlations

A Correlation between soft tissue thickness and Compton scattering counts from the Ag
x-ray was identified. We sought to validate this finding using MC simulation and our
phantom measurements. We did measurements with MC simulation using Lucite and
plaster-of-Paris, and produced a correlation with Compton scattering counts from the
peak at 20.5 keV. We did this same thing experimentally using Lucite slabs and our
plaster-of-Paris phantoms. We normalized the MC simulation results, so that they would
be comparable, and the comparison can be seen in Figure 2.9. The disagreement in higher
thicknesses could arise from a discrepancy from our Lucite slab thickness measurements,
how the simulation handled Compton scattering interactions, or uncertainty from the
simulation. Uncertainty in the simulation was about 5% per channel in our spectrum.
Given the discrepancy in the simulation results of soft tissue and Lucite, this likely
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reflects a similar error in how the Lucite is simulated or the Compton scattering crosssection with Lucite is calculated. This discrepancy would not affect our calibration,
because we are not directly using the estimated soft-tissue thickness for anything, but
only how it relates to the rest of the spectrum.
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2.50E-05
2.00E-05
1.50E-05
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Phantom Lucite
Experimental

5.00E-06
0.00E+00
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6

Lucite Thickness (mm)

Figure 2.9 Compton scattering counts versus Lucite thickness comparison between
simulation and experimental results.

2.3.4

Minimum Detection Limit Optimization

We did multiple tests for the minimum detection limit optimization using both MC
simulations and experimental results. Our MC simulations were looking at a number of
parameters for optimization. We have max energy of the x-ray tube and filters, as our
variables to modify, and used dose and signal produced from a 100 ppm sample as our
parameters to minimize and maximize for optimization. What we found is shown in
Table 2.1. The best settings without accounting for detector limitations were 40 kV 50
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µA with a filter of aluminum and iron which produced the best results, and the settings of
50 kV 40µA with a filter of Ag and iron being 1.5 times lesser with our parameters of
dose and signal. This unfortunately was not the case, as simulation does not reproduce the
experimental setup flaws such as detector resolving time (dead time), which is why it was
necessary to do further testing with the experimental setup.

Table 2.1 MC simulation optimization of x-ray tube settings results.
50 keV 40 µA
Ag Filter
9.91E-08
2.52E-06
2.40E+05

Total Dose (MeV)
Unnormalized Signal
Signal/Sqrt(Dose)

50 keV 40 µA
Al Filter
1.40E-07
1.67E-06
1.34E+05

40 keV 50 µA
Ag Filter
5.84E-08
2.30E-06
3.56E+05

40 keV 50 µA
Al Filter
7.05E-08
3.24E-06
4.57E+05

Using experimental tests we needed to test our results. We did this by using a
calculation of minimum detection limit for each setting after measuring a 0 ppm and 100
ppm phantom. The detection limit was calculated as
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, and BKG0ppm is the background count rate under the Lα or Lβ peak for the 0 ppm
phantom and GROSS100ppm is the total count rate under the Lα or Lβ peak for the 100 ppm
phantom.
These tests revealed that the settings with 50 µA produced results that were better
than those from 40 µA, but the dead time of the detector was up to over 70% in some
cases for 50 µA. This is unacceptable especially for a phantom measurement. It is
generally accepted that phantom measurements should have about ~15% dead time,
because in vivo will always become significantly higher with the increased scatter from
soft tissue and larger sample size. We thus went on taking into account the dead time in
our measurements as another parameter for optimization. We found that 50 kV 40 µA
with a Ag and iron filter produced the best results.
We measured the detection limit of both our portable XRF devices to quantify the
improvements made in the device detector and geometry and those measurements can be
seen in Table 2.2 below.

Table 2.2 Detection limit comparison between XL3 and XL3t GOLDD+.
Soft Tissue
Thickness
(mm)
0mm
1mm
2mm
3mm
4mm
5mm

Detection
Limit XL3t
GOLDD+
(ppm)
1.2
1.8
2.9
4.6
8.0
11.0

Detection
Limit XL3
(ppm)
2.0
3.5
5.9
9.6
12.8
14.7
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2.3.5

Validation of Portable XRF

Measurements were made to validate the portable XRF system against the standard
KXRF systems for in vivo bone Pb measurements. Phantoms, goat bones, and cadaver
bones with 0, 1, 2, and 3 mm of Lucite were measured by both the portable XRF system
and KXRF bone Pb measurement systems, with goat bone also being measured at 4 and 5
mm of Lucite thickness. Table 2.3 shows the measured phantom Pb concentrations at
different Lucite thicknesses. The correlation (R-squared) between the expected
concentrations and those measured with portable XRF system ranges from 0.991 to 0.999
for soft tissue thicknesses of 0 to 3 mm, demonstrating a good agreement of Pb
concentrations determined by KXRF and portable XRF for bare and Lucite covered
phantoms. An example of this is seen in Figure 2.10 with the 3 mm Lucite thickness
phantom measurements. The quantified results are also accurate and deviations from the
standard phantom concentration is reflected in our calculated uncertainty values.

Table 2.3 Phantom Pb concentrations calculated using the background subtraction
method.
Standard
Phantom ppm
0
5
10
15
20
30
50
75
100

0mm
-0.38±0.8
4.83±0.86
10.23±0.9
14.9±0.94
19.52±0.97
31.32±1.06
47.45±1.17
75.56±1.33
96.96±1.44

Lucite Thickness
1mm
2mm
-0.1±1.3
3.57±1.34
10.5±1.39
13.3±1.4
19.17±1.46
30.09±1.53
52.76±1.7
77.44±1.85
108.65±2.02

-2.22±2.1
9.61±2.19
11.23±2.19
20.37±2.27
21.25±2.27
30.35±2.36
49.43±2.48
74.49±2.65
105.26±2.84

3mm
3.31±3.31
7.37±3.37
17.83±3.42
13.39±3.41
17.37±3.46
32.34±3.56
48.54±3.7
74.34±3.82
101.73±4.06
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Figure 2.10 Phantom calculated concentration versus known concentration for
measurements with 3 mm of Lucite thickness.

Table 2.4 and 2.5 demonstrate the ability of the three calibration methods to
quantify bare cadaver bone Pb values. Table 2.4 shows the Pb concentration in bare
cadaver bone calculated using the three calibration methods. Table 2.5 shows the bone Pb
concentrations for cadaver Bone covered with 3 mm of Lucite. Without Lucite the
calibration methods tend to be fairly similar, but with the introduction of Lucite the bone
adjustment method tends to get further from KXRF values by overestimating background
levels, which is from an overcorrection of the Compton scattering peak. Bone calibration
has a similar correlation, but with only 4 points on the calibration line and the highest
point at 31.4 ppm the actual values tend to deviate from KXRF. Higher concentration
standards are necessary to get visible signal while defining our function to correct for the
inverse square and attenuation signal degradation as soft tissue increases. Background
subtraction was the most reliable calibration method for higher Lucite thicknesses and

40
lower Pb concentrations, which was determined using the correlation values for the
cadaver bone evaluated at different Lucite thicknesses.

Table 2.4 Bone Pb concentrations for bare cadaver bone calculated using different
calibration methods.
Cadaver
Bone
ID
6900
7202
6918
7131
7031
7162
7042
7002
6895
7168

KXRF

Background
Subtraction

Bone
Calibration

Bone
Adjustment

23.12
22.17
21.17
20.77
19.70
18.36
14.27
13.54
9.82
3.64

23.44
19.23
9.35
25.59
24.09
17.91
16.05
15.29
15.91
1.08

23.63
19.94
11.30
25.53
26.18
18.81
18.33
16.48
17.04
3.82

22.21
18.48
9.50
24.34
23.39
17.48
16.10
15.15
15.59
-1.86

Table 2.5 Bone Pb concentrations for cadaver Bone covered with 3 mm Lucite
Cadaver
Bone
ID
6900
7202
6918
7131
7162
7002
6895

KXRF

Background
Subtraction

Bone
Calibration

Bone
Adjustment

23.12
22.17
21.17
20.77
18.36
13.54
9.82

20.92
16.72
2.97
18.10
12.07
10.80
12.94

22.44
18.53
-1.35
11.76
6.55
13.55
14.69

11.66
8.14
-14.21
9.61
4.33
3.25
5.26

Figures 2.11-2.16 show the comparison of the correlations between goat bone Pb
concentrations calculated by KXRF and portable XRF at Lucite thicknesses of 0-5 mm,
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with the Pb concentrations for portable XRF being calculated using traditional peak
fitting or background subtraction. From the correlations, one can see that traditional peak
fitting does fairly well for bare bone or at lower Lucite thicknesses, but with higher
Lucite thicknesses the correlation falls off quickly due to the high background leading to
the Pb peak being highly distorted especially at low concentrations. The chi-squared
values for all the spectral fittings are close to 1, with the average chi-squared and
standard deviation of the chi-squared value for these fits being 1.1±0.4, which
demonstrates that even for poor results the data is accurately represented by fitted
function.
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Figure 2.11 KXRF versus portable XRF bone Pb measurements for bare goat bone.
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Figure 2.12 KXRF versus portable XRF bone Pb measurements for goat bone with 1 mm
of Lucite thickness.
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Figure 2.13 KXRF versus portable XRF bone Pb measurements for goat bone with 2 mm
of Lucite thickness.
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Figure 2.14 KXRF versus portable XRF bone Pb measurements for goat bone with 3 mm
of Lucite thickness.
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Figure 2.15 KXRF versus portable XRF bone Pb measurements for goat bone with 4 mm
of Lucite thickness.
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Figure 2.16 KXRF versus portable XRF bone Pb measurements for goat bone with 4 mm
of Lucite thickness.

The data for cadaver bones with different Lucite thicknesses analyzed using the
background subtraction method is presented in Table 2.6. The correlations (R-squared)
between the concentrations obtained from KXRF and those from the portable XRF
system range from 0.58 to 0.94 with Lucite thicknesses of 0 to 3 mm shown in Figures
2.17 and 2.18 respectively. The correlations between the Pb concentrations obtained from
KXRF and portable XRF are worse for the cadaver bones than for the goat bones. This is
mainly due to the lack of Pb concentration variation among the cadaver bones and
geometric stability. Also, cadaver bone 6918 is an outlier (see discussion).
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Table 2.6 Bone Pb concentrations for cadaver bones with different Lucite thicknesses
calculated from the background subtraction method.

Portable XRF Bone Pb Result (ppm)

Cadaver
Bone
6900
7202
6918
7131
7162
7002
6895

Background Subtraction with Lucite Thickness
KXRF
0mm
1mm
2mm
3mm
23.12
22.17
21.17
20.77
18.36
13.54
9.82

23.44
19.23
9.35
25.59
17.91
15.29
15.91

24.54
22.02
13.05
20.9
18.5
14.48
13.86

19.49
14.56
5.96
21.68
16.32
14.54
10.31

20.92
16.72
2.97
18.1
12.07
10.8
12.94
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Figure 2.17 KXRF versus portable XRF bone Pb measurements for bare cadaver bone.
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Figure 2.18 KXRF versus portable XRF bone Pb measurements for cadaver bone with 3
mm of Lucite thickness.

To test the reliability and reproducibility of the technology for in vivo
measurement, the cadaver bones with intact soft tissue were measured repeatedly. Only
three such cadaver bones were available in our lab, so there are limited data for this test.
Table 2.7 shows the Pb concentrations from LXRF and KXRF for the three cadaver
bones with intact soft tissue. The bones were measured nine times using the portable
XRF device. The comparison in Table 2.7 demonstrates the abilities of the device in use
through actual soft tissue. Using the Compton peak to determine soft tissue thickness,
which was shown to be comparable to an ultrasound measurement, we found the intact
soft tissue thicknesses for our three cadaver bone samples to be 1.3 mm for cadaver bone
7042, 4.1 mm for cadaver bone 7031, and 5.6 mm for cadaver bone 7168. The higher
errors for individual measurements and higher standard deviation for grouped
measurements are associated with larger soft tissue thicknesses, which is what we expect.
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Table 2.7 Bone Pb concentrations for three intact cadaver bones measured by portable
XRF for 9 times, comparing to those measured by KXRF.
Cadaver Bone (ppm)
7031
7168

Cadaver Bone ID

7042

KXRF

14.27±1.19

19.7±1.04

3.64±1.07

1
2
3
4
5
6
7
8
9
Average±SD
Soft Tissue
Thickness (mm)

14.55±1.68
15.42±1.69
14.75±1.68
12.58±1.66
10.98±1.65
14.69±1.67
13.2±1.66
12.44±1.64
12.5±1.64
13.46±1.46
1.3

17.69±4.74
16.4±4.72
17.75±4.66
13.63±4.68
22.86±4.79
18.13±4.87
24.15±4.95
17.67±5
15.55±5.01
18.2±3.34
4.1

7.07±10.51
5±10.44
15.8±10.67
12.93±10.64
12.24±10.57
16.2±10.71
6.89±10.54
11.58±10.75
24.25±10.76
12.44±5.93
5.6

2.3.6

Discussion and Conclusions

This chapter investigated the optimized detection limit of a portable XRF system for in
vivo bone Pb quantification and validated the system using phantoms, goat bones, and
human cadaver bones. The improved system geometry and detector size greatly enhanced
the detection limit of the device and the ability of the device to accurately determine the
concentration of Pb in bone especially at the in vivo situation.
The comparison between simulation and experiment of phantom materials pointed
out some potential flaws in using it as a comparison directly for our portable XRF. The
main flaw with the simulation is verifying the geometry of the experimental device and
inputting it correctly into the simulation. The angles between detector and sample are set
rigidly in the experimental setup and result in slight differences in energy. Along with
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that we do not know if they use some type of shielding surrounding the detector itself,
which would help to lower background, and cannot input the exact detector parameters
like resolution and resolving time into the simulation. These differences all led to slight
changes in what could account for some of the error observed between Lucite and soft
tissue in simulation versus our experimental result.
The detection limit for the portable XRF device is improved from the previous
portable XRF device by a factor of about 2. Through soft tissue thicknesses of 4 mm the
device has the capability of a detection limit of 8 ppm, which is comparable to detection
limit of 6-10 ppm with KXRF bone Pb measurement systems in most labs. It is also
relevant to point out that this was with a 3 minute measurement time, and that time could
be increased by a factor of 2 or 3 to lower the detection limit further, while maintaining a
reasonable radiation exposure. The main disadvantage of LXRF systems is the lack of
penetration of the low energy x-rays and thus at depth, the ability of the system to
determine concentration becomes limited. The average range for the energy of our x-ray
tube in cortical bone is 1.3 mm and for soft tissue thickness is about 12.5 mm. With this
system, it is shown that even at depths of 4 mm of soft tissue the portable XRF device
now has the capability of obtaining measurements in 3 minutes, which would be
equivalent to a KXRF device with a 30 minute measurement. In studies it has been shown
that tibia measurement sites with tissue thickness of less than 4 mm can be found on most
seniors and about half of the general population [47, 49]. One of our target populations
for this device is the senior people whose mobility might be confined by their health
conditions. Another point of clarification is the fact that with the low penetration depth of
LXRF, the KXRF and portable XRF systems are sampling different sites of the bone.
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KXRF would be sampling the whole bone and LXRF would be sampling the superficial
0.5-1 mm of the bone. It is not very clear how Pb distributes over the layer of tibia bone
and the literature on this topic is limited. Todd et al. showed higher concentrations of Pb
at 1-2 mm to the surface in bone [50], while Bellis et al. demonstrated a higher
concentration of Pb at a much thinner layer [51]. While the bone Pb concentrations from
KXRF and LXRF are highly correlated in our study, further investigation with larger
amount of samples is needed on the comparison for the absolute bone Pb concentrations
from these two methods. It is also relevant to point out that with measurements of bone
Pb the goal is a correlation with health effect, which should be reflected in both surface
and depth bone measurement sites.
Another point of potential difference is revealed in the units of measure of the
results obtained for each device. The KXRF bone Pb measurement system has a unique
normalization based on the energies of the excitation source, which allows it to be
normalized specifically to the bone matrix that was irradiated during the measurement
and can give results in µg/g bone mineral, which is equal to ppm units in most cases. The
portable XRF calibration is done using phantoms of known concentrations in ppm;
however, no normalization can be done to the irradiated portion of bone in particular
since no spectral features are stable enough to be consistently changing with bone with no
other relation to soft tissue or other compositional differences. This is due to the energy
of the portable XRF. From past discussions comparing plaster-of-Paris and in vivo bone
measurements, there should be a factor of about 1.5 between the two results. This factor
converts the measured matrix from bone mineral to dry bone. In our measurements it
appears that for the cadaver bone measurements this factor is non-existent, which should
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not be the case. The portable XRF device with results from the phantom calibration
should be in µg/g dry bone, which should need to be converted to µg/g bone mineral;
however, plaster-of-Paris is not exactly equivalent to dry bone, which could further
influence this relation. The units will need more investigation, but will not influence the
relevance of our correlations, as the values should still correlate well regardless of unit
conversions.
The Pb concentrations found through KXRF and portable XRF measurements of
bare bone show good correlation. In order for our device to determine the in vivo Pb
concentration, our analysis methods should prove to be accurate with bone. Bone has
different density and effective atomic number compared to our calibration phantoms,
which led to differences in its resultant XRF spectrum. Our results with simulation and
then measurement of cadaver and goat bones show that our calibration methods
adequately address these differences as the results are well correlated with KXRF data. In
comparison, the traditional peak fitting calibration method results are shown with goat
bones, and at larger Lucite thicknesses this method is worse than the background
subtraction method especially for low concentrations of Pb. It is relevant to point out that
other studies exploring the validity of LXRF for Pb studies used traditional peak fitting
methods and showed that the results were not reliable especially at higher soft tissue
thicknesses [32]. The main issue is with the fitting program’s ability to discern
background from the Pb peak region, which is increasingly difficult at higher background
levels. It is much more difficult to fit the alpha region in these cases as well, since the
alpha region tends to have much more noise from surrounding elemental characteristic xrays like selenium and zinc, which further confound the area where the peak should be.
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Beta regions tend to have less interaction with other characteristic x-rays and showed a
better ability to be fit in low concentration and high tissue thickness situations, although
still with limited accuracy.
The background subtraction calibration method performed the best in our study.
The bone adjustment method did correct the Compton peak to phantom values for a more
equal comparison, but it fails to take into account the balance between the Compton peak,
background, and signal, and because of this, at higher Lucite thicknesses it exaggerates
the problems seen with background subtraction of overestimating the background under
the Pb peak regions. This is because the calibration itself is just trying to fix the Compton
peaks to reflect phantom values, but the extent of this difference is not just from bone and
will not be reflected only in the Compton scattering peak. If the interaction cross section
of the bone should change for Compton scattering, it will also change for photoelectric
absorption thus changing our signal. The bone calibration only adjusted for changes in
Compton scattering, which did not reflect the bigger picture of what was happening in
our spectra. Bone calibration should be the best calibration method in theory since it is a
comparison of two bone matrices, but due to the lack of standard bones with higher Pb
concentrations, the calibration line for this method tended to produce results that were
less accurate than the background subtraction method. There were only 4 goat bone
standards we could use for this and with that only a 31.4 ppm maximum concentration.
Using this method effectively lowers our ability to detect low levels of Pb. A 31.4 ppm
standard can only be accurate to a certain Lucite thickness. Reviewing the sample
spectrum in Figure 2.5 gives you a sense of this. That sample spectrum is with 14 ppm
and 1.3 mm, so at about 3 mm the Pb x-ray peaks will be almost invisible with the
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background noise. Similarly, a 31.4 ppm phantom at 5 mm of Lucite thickness will be
almost invisible. This will limit the statistical value you can place on your calibration line
at 5 mm of Lucite thickness and the uncertainty will be much higher than if a 100 ppm
phantom was used.
The correlation of bone Pb concentrations between KXRF and portable XRF is
very good for phantoms and goat bones with Lucite thickness up to 5 mm, while the Rsquared degraded slightly for our cadaver bone measurements. This is mainly due to the
small variation of the Pb concentration for these cadaver bones, as well as the difficulty
to adjust the geometry of the bare bones. In measuring cadaver bones, the geometry
presented issues if not strictly monitored. We found that the cadaver bones were prone to
air gaps in the geometry, which led to significant changes in the spectrum caused by the
increased distance without significant attenuation. This can cause significant drops in our
quantification. From Figure 2.19 below, we can see that a 2 mm gap could cause a drop
from inverse square law effects of almost 50% of the signal, which would introduce an
error of ~50% in our measurement. Although this effect was visible in the cadaver bone
data, given the geometry of in vivo measurements this effect would not be present as the
bone is covered in soft tissue, so there will not be air gaps between the soft tissue and
bone in vivo. The geometry will always be conserved with the portable XRF pushed
against the soft tissue covering the bone. Attenuation by soft tissue is accounted for with
our calibration by determining the soft tissue thickness from the Compton peak, which inturn corrects for distance, as the gap between the detector and bone is filled with soft
tissue. The main issue with the cadaver bones was this gap was not filled with anything
and thus could not be accounted for unless we knew the exact air gap.
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Figure 2.19 Net Pb beta counts versus Lucite thickness

Although only three intact cadaver bones were used to test the reproducibility of
the system for bone Pb quantification and to validate the system in a real in vivo situation,
several conclusions can be drawn from these limited data. First, this set of data confirmed
the validity of the system for in vivo measurements, especially for the measurements with
soft tissue thicknesses less than 5 mm. Second, the data confirmed that the thickness of
the soft tissue significantly affect the uncertainties of the resultant concentrations. The
standard deviations from the repeat measurements are lower than the uncertainties for
individual measurements, which indicate the uncertainties for individual measurements
maybe overestimated. In addition, the detection limit of the measurements calculated
from the Pb concentration uncertainties (DL = 2 x sigma) for cadaver bones listed in
Table 2.7 would be higher than those listed in Table 2.2 for corresponding soft tissue
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thicknesses. This is because the uncertainty calculated in Table 2.7 includes the error on
the gross count and net count of the signal under the Pb L x-ray peak, while the DL
calculated in Table 2.2 only includes error associated with the background of a blank
phantom covered with a corresponding thicknesses of Lucite. Nonetheless, this data set
shows an excellent agreement of bone Pb concentrations for cadaver bones at thickness
of 1.3 and 4.1 mm, while the agreement deteriorates at 5.6 mm. The disagreement
between standard deviation of measurements and calculated uncertainty likely arises from
a number of different places. As stated previously the measurement uncertainty
calculation takes into account the uncertainty of gross and net counts, which is likely
staying similar since it is the same measurement site. The same measurement site will
have the same physical properties and interaction cross-sections for our portable XRF,
which is why it reflects similar measurements. In reality we will be comparing different
in vivo measurement sites for different individuals, which will need to be reflected in an
associated uncertainty for these potential differences.
In the cadaver bone measurements, there is one bone (cadaver bone 6918), which
we considered an outlier in our dataset. This bone came from a 100 year old female, and
presents further challenges with the LXRF device. The spectrum from the bone had a
much higher than normal Compton peak, which we attributed to the bone appearing more
like soft tissue with respect to the spectral features. This resulted in a more pronounced
overestimation of the background, and worse signal quantification. In general the
background subtraction method should overcome slight variations in bone between
individuals, as the Compton peak will also relate back to the material of the bone. The
relationship we had derived between the Compton peak and the Pb signal broke down for
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this particular bone. We found that the density of this bone was significantly different
than the others, but have not identified a way to counteract this difference with our
calibration methods. Although bone 6918 has a Compton peak that is significantly
different, other spectral features show differences that may be able to be exploited to
correct the issues with the Compton peak in this spectrum.
The portable XRF system, now with a significantly lower detection limit, has its
main advantages over KXRF with its portability, acquisition times, and ease of use. The
new system can achieve a minimum detection limit equivalent to a KXRF measurement
through tissue thicknesses up to 5 mm. The portable XRF system also has the advantage
of using an x-ray tube, which can be turned off when it is not in use and is less
complicated for radiation licensing than a radioisotope source. The portable device lends
itself for use in epidemiologic studies because of its quick measurement times and
portability. The device allows for on-site Pb surveys and risk assessments of the
environment, while performing exposure assessment of the community members.
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CHAPTER 3. XRF MEASURED BONE PB AS A BIOMARKER FOR A PB
POISONED PEDIATRIC POPULATION

3.1

Introduction

Despite strict standards for Pb use in many countries, childhood Pb poisoning remains a
worldwide issue. This problem is more prevalent in heavily industrialized areas. China, in
particular, presents unique exposure issues: pollution, alternative medicines with large
amounts of Pb used to treat various diseases, and ever-increasing consumer and industrial
usage of Pb containing products. Recent studies show that Pb exposure results in
significant decline in intellectual ability even at low-levels, and that the Pb associated
intellectual decrement was steeper at low blood Pb levels than at higher blood Pb levels
[5, 6, 52]. These studies use blood Pb as a biomarker, which assesses recent exposure and
has a half-life of about one month in adults [44]. Cd-109 based K-shell x-ray
fluorescence (KXRF) has been used to study bone Pb for over two decades, but not many
studies have been performed on children using a bone Pb biomarker, and the studies that
do exist have a relatively high uncertainty and were not able to detect bone Pb in most of
the subjects due to the high uncertainty of the conventional bone Pb measurement system
[53, 54]. There is a significant gap in understanding children’s bone Pb measurements
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and their relationship to blood Pb, as well as the usefulness of bone Pb as a biomarker for
Pb exposure and toxicity among children, which are addressed in this chapter.
This chapter focuses on a study of a group of Pb poisoned children recruited from
Xinhua Hospital in Shanghai, China. The children were tested for bone Pb with the
modern cloverleaf KXRF measurement system and the portable XRF bone Pb
measurement system. With the low detection limit of the advanced KXRF system we can
identify the role of bone Pb in children’s Pb biokinetics, and using a comparison with
portable XRF results we can assess the ability of its use in measuring children’s bone Pb
levels. This addresses the need for identification of Pb’s roles in development and how it
stores in the body of children.

3.2

Materials and Methods

3.2.1

Study Population

The study participants were Pb-exposed children and controls recruited through Xinhua
Hospital, Shanghai Jiaotong University, China. The Pb-exposed group was recruited from
children who were diagnosed as Pb poisoned with blood Pb levels >25µg/dL. Some of
these children had already undergone multiple treatments prior to our first measurements,
and some were measured at the time of their first treatment. The controls were recruited
from children who visited the clinic for non-Pb related diseases. Xinhua Hospital has a
specialized environmental health department, so children from all over the country in
need of treatment would come to this hospital. The parents of the subjects completed a
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questionnaire, and the subjects had their blood samples taken, and their bone measured
for Pb concentration using an advanced cloverleaf Cd-109 KXRF as well as a portable xray fluorescence (XRF) system. Blood Pb was also measured for these children. Some of
the Pb-exposed children were treated using ethylenediaminetetraacetic acid (EDTA)
chelation. These treatments were done at the hospital and the patients were monitored
during the process that lasted a few days. After treatment, some patients would return
after 41.5±30.0 days for another round of treatments and they would be measured again
for bone Pb using the Cd-109 KXRF system.
The study received IRB approval from Purdue University and Xinhua Hospital.
When recruited, a trained research assistant would present the subjects and their parents
with the details of the study and the consent forms. Signed consent forms were received
from the parents of each subject, as well as an assent form from any child age 7 or older.

3.2.2

KXRF Bone Pb Measurement System

The KXRF bone Pb measurement system was used to measure tibia bone Pb as a metric
of each individual’s cumulative Pb exposure. The system was the same as described in
Chapter 2. Before measurement, the subjects’ legs were cleaned using alcohol and EDTA
cotton swabs to remove any Pb contamination. For the KXRF measurement the subject
would sit on a wooden chair. The subject’s leg was immobilized by using two Velcro
straps to attach their leg to the leg of the chair at the ankle and just below the knee. The
measurement site was mid-tibia with the source at a distance to maintain ~30% dead time
during the measurement. The system was on a moveable platform that could be used to
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adjust to different placements for each individual. The measurement was taken for 30
minutes while the subject watched a movie. Finally, the spectra were analyzed using the
in-house peak-fitting program, which gave results and error for each of the four detectors
[55-57]. This error and result was combined using inverse variance weighting [58]. XRF
provides a point estimate of Pb concentration, which can be negative if an individual’s
bone Pb is close to zero. It is important to include these negative values, as with their
associated uncertainties they are still a point estimate of that individual’s bone Pb. The
negative values also give us a sense of how well the system is working with the
population. Since children have typically demonstrated to be a population with
measurement problems for bone Pb, it is important to identify the associated uncertainties
in our measurements and the lowest limit for measurement in this population.

3.2.3

Portable XRF Bone Pb Measurement System

The portable XRF used in this study was the XL3t GOLDD+ system identified in
Chapter 2. We used the optimized x-ray tube settings discussed in Chapter 2 for this
study and used a two-minute measurement time. Before measurement, the subjects’ legs
were cleaned using alcohol and EDTA cotton swabs to remove any Pb contamination.
We again chose the measurement site to be mid-tibia. In placing the device on the
subject’s leg, we used non-Pb based ink to make a dot on the measurement site. This dot
could then be found using a camera mounted in the head of the portable XRF, which
ensured a consistent measurement location. This was also the same site the KXRF
measurement was taken from, since the portable XRF measurement was done first in
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most cases. The subject’s leg was held horizontally with their foot resting in the
operator’s lap during the measurement. The spectra were analyzed using traditional peak
fitting as described in detail in our previous work in Chapter 2. Based on our previous
study, by adjusting values for increased measurement time and tube current we estimated
the entrance skin dose of the system was 21 mSv to a 1 cm2 area and the whole body
effective dose was 2.4 µSv [47]. This dose is less than that of the KXRF system and is the
same for the adult and child subjects. The low energy x-rays used with the portable XRF
do not penetrate into the bone marrow and thus do not have the increased tissueweighting factor of bone marrow in children, which results in a lower radiation dose.

3.2.4

Blood Pb Analysis

Blood Pb analysis for this study was done at Xinhua Hospital. The blood of the subjects
was collected in a Pb-free environment. We cleaned the subjects’ skin using alcohol
swabs before sampling. The blood collection tubes along with the EDTA-K2
anticoagulants were measured to be Pb free before sampling. All the samples were frozen
and kept at -800 C immediately after the collection. Blood Pb concentrations were
measured and analyzed by an Atomic Absorption Spectrometer (AAS) (AA900Z, PE)
[59]. The sensitivity of our device was 0.01µg/dL, and inter and intra assay variability
was 5%.
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3.2.5

Statistical Methods

Linear regressions were used to determine correlation values and levels of significance of
relationships between KXRF and portable XRF bone Pb measurements and KXRF bone
Pb and blood Pb. The KXRF bone Pb data was excluded from our analysis if the final
uncertainty was >10ug/g. This would indicate an excessive amount of movement during
the measurement or a measurement taken for less than 30 minutes. Portable XRF data
was excluded if the measurement time was <2 minutes.

3.3

Results

The study had 269 participants (181 male and 88 female), ranging in age from 1 to 15
years old with a mean of 5.7±3.1 years. Of these participants, 175 were Pb poisoned
subjects and 94 were controls.

3.3.1

Bone and Blood Pb Concentrations from the Study Population

The bone and blood Pb concentrations for the exposed and control groups are listed in
Table 3.1. The average uncertainty in this study for in vivo KXRF bone Pb measurement
was 2.66 ± 1.05, and is shown for each group in Table 3.1 under Bone Pb Sigma. Blood
Pb data shown in this table was taken at the time of the first bone Pb measurement, which
for some exposed subjects was after multiple treatments. Table 3.2 shows the blood and
bone Pb data separated by sex of the participants in the study. There was a nonsignificant difference between male and female groups with a p-value of 0.146, but a
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trend of more bone Pb with females was observed. The uncertainty between males and
females was not observed to have any differences.

Table 3.1 Bone and blood Pb statistics for exposed and control groups in the study
population.
Exposed
Blood Pb
(µg/dL)
Bone Pb
(µg/g)
Bone Pb
Sigma

N

Minimum

Maximum

Mean

Std.
Deviation

182

0.80

91.60

20.78

14.08

175

-22.64

244.33

22.40

31.65

175

1.49

9.78

3.42

1.70

77

0.80

9.90

2.91

2.18

94

-9.59

9.38

-0.95

3.50

94

1.67

7.79

2.73

0.86

Control
Blood Pb
(µg/dL)
Bone Pb
(µg/g)
Bone Pb
Sigma

Table 3.2 Bone and blood Pb statistics for male and female subjects in the study
population.

Male
Female
Total

N

Mean

181
88
269

12.6
17.6
14.2

3.3.2

Bone Pb (µg/g)
Minimum Maximum
-22.6
-8.4
-22.6

186.0
244.3
244.3

Standard
Deviation
24.8
33.3
27.9

Blood Pb Correlations with Age

We performed a regression of blood Pb versus age and found a significant negative
correlation as seen in Figure 3.1. Figure 3.2 shows this correlation to be weaker, but still
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significant for KXRF bone Pb and age. The p-value for both of these correlations was
<0.001.

1000
Blood Lead (µg/L)

800

R² = 0.15364

600
400
200
0
-200

0.0

2.0

4.0

6.0

8.0

10.0

12.0

14.0

16.0

Age (yrs)

Figure 3.1 Age versus blood Pb for our study population.
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Figure 3.2 KXRF bone Pb versus age for our study population.
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3.3.3

Correlations Between Bone and Blood Pb Concentrations

Figure 3.3 shows the correlation between bone Pb concentrations obtained from KXRF
and blood Pb concentrations using all subjects. No correlation was found in this
relationship when using only control subjects, and only a slight positive change in
correlation value when using only exposed subjects (R2=0.612). Figure 3.4 shows the
significant correlation for portable XRF measured bone Pb and blood Pb using only
exposed subjects. This is a weaker correlation for reasons explained in the discussion. No
correlation was found in this relationship when using only control subjects, and only a
negative change in correlation value when using only exposed subjects (R2=0.07). The pvalue of both regressions was <0.001.
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Figure 3.3 KXRF bone Pb versus blood Pb measurements for exposed patients.
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Portable XRF Bone Pb (ppm)
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Figure 3.4 Portable XRF bone Pb measurement versus blood Pb.

3.3.4

Correlations Between KXRF and Portable XRF Measured Bone Pb

Figure 3.5 shows the correlation of bone Pb obtained by KXRF versus that obtained by
portable XRF using only exposed subjects. Again with this relationship, no correlation
was found when using only control subjects. The p-value of this regression was <0.001.
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Portable XRF Bone Pb (ppm)
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Figure 3.5 Portable XRF bone Pb result versus KXRF bone Pb result.

3.3.5

Bone Pb and Blood Pb Biokinetics

With the bone Pb and blood Pb concentration data obtained from the study, we can
estimate the percentage of bone Pb over the total Pb amount in blood and bone, which are
two of the largest Pb storage sites in the human body, as well as the Pb transfer rate
between bone and blood. Total bone Pb and blood Pb amount were calculated by
multiplying bone and blood concentrations and the bone mineral amount and blood
volume. The total bone mineral was calculated from the data shown in Specker et al.’s
paper [60]. Specifically, it was calculated using a combination of age, height, weight, and
other variables as shown in the paper. The age, height, and weight of the subjects were
collected in our study. The other variables were estimated from the average values
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corresponding to our age group. The calculation was done by first using their equations
for calculating total body bone area (TBBA) as shown below with our substitutions.

!""# = −359.66 + 7.89 ∗ ! + 25.26 ∗ ! + 54.255 + 19.21

,where -359.66 was intercept, 54.255 was their averaged value for body fat percentage,
19.21 was their averaged value for calcium intake, H is height, and W is weight for our
study participants. Then we can input the results from that equation into our final formula
for total body bone mineral content (TBBMC).

!""#$ = 153.25 + 0.81 ∗ !""# + 16 ∗ ! − 3.52 ∗ ! + 4.09 ∗ ! − 113.15

, where 153.25 is the intercept, A is age, and 113.15 is their value for body fat percentage
combined with its respective weighting factor. The total blood volume (TBV) for each
child was calculated from the data shown in Linderkamp et al.’s paper [61]. Specifically,
it was calculated using an age dependent logarithmic model, which relates blood volume
to weight and height. Again, the age, height, and weight were collected in our study. The
final formula used is shown below.

!"# !"# = 0.6459 ∗ !"#$ + 0.002743 ∗ ! + 2.0324

Then, using the 49 subjects that met the previous criteria and had sufficient data to
calculate the total body bone mineral content and blood volume levels, we found that
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total bone Pb on average accounted for 96±5% of total blood and bone Pb burden. The
maximum and minimum values calculated for each individual exposed subject were 99.5%
and 69.7% total body Pb burden from bone Pb respectively. Separating the subjects by
age we see larger variation in this value with exposed subjects of 1-3 years old with
92.3±11% bone Pb and exposed subjects 3+ years with 96.5±4% bone Pb.
Throughout the course of the study some subjects returned for one to three
treatments, there was a time gap of 41.5±30.0 days (minimum: 7; maximum: 97) between
these treatments. We can assume that bone and blood Pb had reached equilibrium by the
second visit, which then allowed us to calculate an estimated half-life of blood Pb.
Possible sources of Pb exposure were removed from these children after their first
treatment and the effects from chelation should have worn off, so the calculated half-life
is expected to be the biological half-life without significant external exposure sources or
effect from chelation therapy. The bone-remodeling rate (BMR) for children was
calculated from the data shown in ICRP 70 [62]. We plotted the bone-remodeling rate
versus age for children 0-15 years old, fitted the data with second-degree polynomial
function, and calculated the bone-remodeling rate for each child from the fitted line. The
formula for this function is below.

!"# = 0.469 ∗ !! + 13.417 ∗ ! + 116.08

Assuming that bone and blood Pb were in equilibrium, that the Pb from other organs to
blood is negligible compared to the Pb from bone to blood, and that there was negligible
exposure from external sources, the Pb transferred from bone to blood would be equal to
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the Pb transferred from blood to urine, feces, and other organs per unit time. This can be
expressed as:

!!"##$ !" ×!!"##$ !" = !!"#$→!"##$ ×!!"#$ !"

Where !!"#$ !" is total body Pb in bone (total bone mineral × bone Pb concentration
obtained from KXRF in unit of µg/g bone mineral), !!"##$ !" is total body blood Pb
(blood volume × blood Pb concentrations obtained from AAS), !!"##$ !" is the
percentage of Pb in blood which would be transferred to urine, feces, and other organs
per day, and !!"#$→!"##$ is the percentage of Pb in bone which would be transferred to
blood per day. Because the bone resorption rate represents the percentage of bone that
would be resorbed to blood, !!"#$→!"!!" is equivalent to bone resorption rate, which can
be calculated as described before. From these we can calculate !!"##$ !" :

!!"##$ !"#$ =

!!"#$→!"##$ × !!"#$ !"
!!"##$ !"

Given that

!!"##$ !" =

!"(2)
!!/!,!"##$
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where T1/2,blood is the biological half-life of Pb in blood. The half-life of Pb in blood can
be calculated as Ln(2)/λBlood Pb. The half-life was calculated for all the exposed subjects
that had all the necessary measurements to perform the calculation, which resulted in 17
calculations of the half-life. The data and results for those subjects are shown below in
Table 3.3 and 3.4.

Table 3.3 Exposed subject data for blood Pb half-life calculations.

129.6

Second
Blood Pb
(µg/L)
758

Total
Bone Pb
(mg)
39.4

Blood Pb
Half Life
(days)
3.74

303.1

56.0

238

17.0

2.90

0.84

333.0

17.5

195

5.8

8.16

82

0.85

343.4

75.7

223

26.0

2.33

12.5

92

0.98

423.6

69.1

291

29.3

4.13

2.8

17

92

1.20

534.7

89.6

309

47.9

3.30

2.8

14

95

1.08

469.9

186.0

615

87.4

3.25

2.9

12

91

0.95

411.3

19.3

173

8.0

9.13

3.4

20.5

108

1.50

675.5

34.9

245

23.6

5.09

3.4

17.5

106

1.34

596.5

13.8

195

8.2

15.36

4.7

22.5

116

1.67

769.3

33.9

238

26.1

7.19

4.9

16

103

1.24

575.2

19.0

228

10.9

9.35

5.2

16

110

1.29

599.9

60.0

420

36.0

9.88

6.6

25

132

1.98

906.9

59.8

461

54.3

13.05

6.8

35

125

2.36

1135.4

53.2

247

60.4

8.65

11.9

36

150

2.81

1313.2

14.4

294

18.9

51.13

Age
(years)

Weight
(kg)

Height
(cm)

Total Blood
Volume (L)

Total Bone
Mineral (g)

Bone Pb
(µg/g)

1.3

10

80

0.79

303.9

1.4

10

79

0.79

1.6

10.9

80.5

1.9

11

2.8
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Table 3.4 Blood Pb half-life split by age group for exposed subjects.

Group

N

Age 1-3
Age 3+
Total

8
9
17

Average
Blood Pb
Half Life
(days)
4.62
16.27
10.45

Standard
Deviation
2.56
14.47
11.71

Along with this data, we estimated the change in bone Pb before and after treatment for
each patient that came back for multiple visits after chelation therapy. This data is shown
below in Table 3.5. There was a non-significant difference between bone Pb before and
after treatment with this data, but we believe this would be more significant with more
cases.

Table 3.5 Bone Pb changes after chelation therapy for different groups in our study
population.

Group

N for
Each
Group

Age 1-3
Age 3-6
Age 6+
Male
Female
Total

20
19
14
37
22
59

Average Bone
Pb Value
Before
Treatment
(µg/g)
38.5
17.6
16.9
27.5
36.4
30.8

Standard
Deviation
43.4
16.6
16.7
35.6
52.7
42.6

Average
Bone Pb
Value After
Treatment
(µg/g)
34.1
16.9
15.7
25.3
29.9
27.0

Standard
Deviation

Total
Bone
Pb
Before

Total
Bone
Pb
After

34.1
16.4
15.7
32.7
37.3
34.2

770.8
334.7
236.5
1018.9
800.0
1818.9

682.4
321.2
220.5
934.6
658.1
1592.6
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3.4

Discussion and Conclusions

This chapter demonstrated the capabilities of in vivo XRF bone Pb measurement on
children. The average uncertainty for the KXRF bone Pb measurement for this population
is 2.66 ± 1.05, which is slightly higher than that for an adult population. This is expected
because there is on average more fatty tissue in a child’s bone and the bone density is
lower for a child’s bone. The portable XRF has a higher detection limit than the KXRF
device used in this study. The detection limit for the portable XRF heavily depends on the
soft tissue of the subject and thus varies more throughout the study [38]. An issue
associated with the anatomical structure of the bone in children, which is illustrated
below, further deteriorated the detection limit for portable XRF.
Correlations between bone and blood Pb and age could have a number of
implications. One possible reason for this observation would arise because the patients
were exposed populations and the short half-life of Pb in blood. The blood half-life is
relatively short compared to bone and thus will have a better reflection of recent
exposures from behavioral differences in ages, such as foot and hand to mouth behaviors.
This can influence the blood Pb values to be higher in the lower age group.
The correlation between KXRF bone Pb and blood Pb shows a higher slope and
stronger r-squared than similar studies with adults [63-66]. One of the reasons for both
these differences could be that children have a higher bone resorption rate, which
indicates a more frequent transition of Pb between bone and blood, and hence their bone
Pb is more significantly correlated with their blood Pb. The more significant correlation
also indicates that for this population the majority of Pb in blood comes from bone. This
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is expected since there is a significant store of Pb in these children’s bones, children’s
bones are well known to have turnover rates higher than that of adults, and the exposure
source has been removed from most cases viewed in this study.
The portable XRF in comparison to the KXRF results gave a correlation less than
what we would expect based on previous observations in adults and lab samples, as well
as what we would have expected given the high Pb concentrations in this study. Since
KXRF is a gold standard for in vivo bone Pb measurement, the correlation between
KXRF and portable XRF demonstrates the limited ability of the portable XRF with
current calibration methods to quantify bone Pb in children. In a previous paper, we
detailed calibration methods and found the best calibration method as determined by inlab samples [35]. In that study we found that the best calibration utilized the Compton
scattering peak in relation to the soft tissue thickness over bone. This technique, although
valid for adults, has complications with children. The Compton scattering peak is much
larger than anticipated with children and thus overestimates soft tissue thickness and
background from our spectrum. We attribute this to differences in composition and
structure of the bone in children. Children are known to have changing bone composition
and density as their bones are developing. Although our phantoms are designed to give
accurate calibration for bone in adults, the differences in children’s may affect our XRF
spectra than we attempted to correct for with calibration [62]. Given this issue, we
applied an alternative calibration for the results shown here, which used traditional peak
fitting of the beta Pb peak, which is also detailed in the previous study of the device [35].
We chose to do this because when looking at the individual spectrum there was a visible
Pb peak in this region with no surrounding elemental peaks for distortion of the signal.
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Calibration could be improved with proper calibration phantoms to reflect the appropriate
anatomy of children’s bone. It is relevant to point out that a similar situation arose with
one particular bone pointed out in Chapter 2. Bone 6918 had been found to have a
significantly different density and gave values for the portable XRF that differed greatly
from the superior KXRF measurement results. Given that the calibration of the portable
XRF used for adults is not suitable for a pediatric population, future measurements of
children using this technology may be feasible, but further investigation on the effect of
bone composition and an improved calibration method would be necessary to obtain
more accurate results.
The effect of bone density on the portable XRF is reflected in two spectral features,
the Compton scattering of the Ag target peaks and the degradation of signal from
characteristic x-rays from bone. The main issue would be the degradation of signal from
characteristic x-rays. We had accounted for a partial degradation from the overlying soft
tissue thickness, but this would be in addition to that by changing the cross section of
interaction in bone directly from the lower density values. One possible solution to this
would be to find some element in bone that produces a characteristic x-ray and has levels
known to be consistent among individuals. We could use that peak then to normalize the
Pb peaks and determine the interactions that actually occurred in the bone. There is no
obvious element for this process, and thus we have used our conventional calibration for
this part of the study, which did prove to show some significance in comparison between
portable XRF and KXRF data. Another possible solution to our calibration problem with
children could be identifying spectral differences in the coherent and Compton scattering
peaks relating to density and composition. This method would rely upon using the known
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cross-section of phantom data for the two interactions based on effective Z and density to
determine a ratio for correction. This would require precise calculation of this ratio and
could possibly utilize simulation to be more effective; however, this has the difficulty of
needing to have known compositional and density differences that one could simulate in
the first place, and unfortunately the exact bone changes that cause the issues are
unknown.

The relationships between KXRF bone Pb and blood Pb and KXRF bone Pb and
portable XRF bone Pb measurements became slightly more positive when isolating based
with only the exposed group. This is because the controls in the study all had values of
nearly zero for both blood and bone Pb. The same relationships with only controls show
no correlation, which can again be caused by the values being close to zero with
uncertainties higher than measured bone Pb values.
The Pb body burden of the children assessed in our study is much higher than that
suggested in other studies, which is expected because these children were Pb poisoned
[53]. Our proportion of grams bone Pb to grams bone and blood Pb results are in
agreement with previous studies of Pb body burden [19], and demonstrates the value of
bone Pb measurements even with children to better reflect body Pb burden.
Only few studies in literature investigated half-life of Pb in blood in children [67,
68]. The half-life of Pb in blood calculated in our study lies in between results from these
previous studies. Manton et al. reported a half-life of Pb in blood ranging from 8-11
months to 2-3 years [67]. This study did not isolate bone Pb from blood Pb and thus may
reflect the long half-life of Pb in bone, since Pb stored in bone would gradually be
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released to blood endogenously. In addition, because the blood Pb levels in those children
were relatively low, a continuous external exposure, even at low level, could contribute to
a prolonged half-life. Duggan’s study reported a much shorter half-life of Pb in blood of
3.35±1.34 days using blood and urine Pb data [68]. However, the data are based on only
two subjects. The half-life of blood Pb in our study is calculated from bone Pb and blood
Pb data using the best bone and blood parameters we could find from the literature. The
data used are the ones taken as far from chelation as possible (41.5±30.0 days after
chelation) to reduce the effect of chelation. However, chelation may still affect the
equilibrium of Pb in bone and blood at that point of time and hence affect half-life of
blood Pb calculated. Also, for our study we were able to isolate the exposure source for
most children, but it is possible some continued to be exposed during this period. A
potential source of error in our study was the bone resorption rate we estimated from
previous studies. Changes in this rate could impact our results by almost a factor of 2 in
extreme cases for the youngest subjects. Even considering this, the value we calculate
would still be much lower than the adult blood Pb half-life published in literature.
The trend of decrease in bone Pb before and after treatment demonstrates the need
for bone Pb assessment for these types of patients. This also has implications on whether
chelation will be able to remove Pb from bone as well as from blood. Monitoring bone Pb
in patients is vital to identifying whether body burden levels will decrease. This is
important as bone Pb could serve as a source of continuing exposure for years to come
for long-term exposed individuals.
In conclusion, bone is a major storage site for Pb in children, and serves as an
indicator of total body Pb burden. KXRF is a viable measure of bone Pb in children with
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detection limits capable of measuring even environmental exposures. Portable XRF has
limitations for bone Pb measurements in children based on calibration, which need to be
addressed before being used further in pediatric populations. Bone Pb contributes
significantly to blood Pb levels in Pb poisoned children and the blood Pb half-life in
children is calculated to be 10.45±11.71 days. The results from the study indicate that
bone Pb may be a better marker for determination of chelation efficacy.
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CHAPTER 4. IN VIVO QUANTIFICATION OF SR IN BONE AMONG A PB
POINSONED PEDIATRIC POPULATION

4.1

Introduction

Strontium (Sr) is a metal that is closely related to calcium (Ca) in the body, which may
have beneficial or toxic effects on bone formation. 99% of strontium is stored in the teeth
and bones after uptake in the body [12, 13]. Low doses of Sr have been reported as being
beneficial to bone and Sr supplementation has been used to treat osteoporosis and
osteopenia [69]. Women have higher probability of developing bone diseases, and
treatment with Sr ranelate had led to a reduced risk of fractures in postmenopausal
women affected by osteoporosis [15, 16]. High levels of Sr have been correlated to
skeletal abnormalities in animals and children, and associated with osteomalacia [11, 70].
Sr exposure is generally limited to oral exposures with Sr chromate being more
dangerous for inhalation because of chromium. The skeletal abnormalities would occur in
malnourished children lacking in sufficient protein and calcium in their diets with the
exposure coming from food grown in soil with >350 ppm Sr [11]. Bone should be a longterm storage site for Sr, and bone is the superior marker for treatment efficacy in Sr
treated patients [15]. Measuring bone Sr is traditionally done using a bone biopsy, which
is a painful procedure unlikely to be completed multiple times [14]. Blood Sr can be used
to measure exposure levels, but it is unlikely to correlate with long-term exposures [71].
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X-ray flourescence (XRF) has been used to measure bone Sr, but this device uses
a radiosotope source, has bulky equipment requiring liquid nitrogen cooling, and a 30minute measurement time [10]. Another technique utilizing the differences in absorption
of photon energies called dual photon absorptiometry (DPA) was able to non-invasively
measure bone Sr, but this device was also fairly large, required 10-minute measurement
times, immersion in water, and produced results in percentage Sr [22]. These systems
both use radioisotope sources, bulky equipment, and require longer acquisition times.
The portable XRF used to measure bone Pb can be similarly applied for measurement of
bone Sr. This chapter demonstrates a calibration of Sr for the portable XRF and uses the
data collected in chapter 3 to verify bone Sr in vivo measurements using a group of
children in Shanghai, China.

4.2

4.2.1

Materials and Methods

Strontium Phantoms

Sr phantoms were made using Mowial-88 and bone meal. This is a similar approach to
that used previously for hand bone phantoms and has been proven to be effective for
calibration phantoms [72]. Mowial-88 acts as a binding agent for the bone meal and is Sr
free. Bone meal easily replicates the bone matrix, since it is ground cow bone. The bone
meal was determined to have a Sr contamination level of around 74 ppm. Sr
contamination in traditional methods using plaster-of-paris lead to Sr levels of greater
than 1000 ppm. A method for producing chemically pure phantoms was found, but
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requires weeks to complete, and requires advanced chemical manipulations [73]. Our
Mowial-88 phantoms had added concentrations of Sr of 0, 5, 10, 15, 20, 30, 50, 75, 100,
and 200 ppm in order to get a calibration line and accurately determine the detection limit
of Sr. Lucite slabs were then used as a soft-tissue equivalent phantom and measurement
of the Sr phantoms at different Lucite thickness was used in the calibration and detection
limit calculations. Measurements were made by using the flat bottom portion of the Sr
phantom with lucite slabs placed between the phantom and the portable XRF.

4.2.2

Portable XRF Bone Sr Measurement System

The system used here was the same as used in chapter 3. We used the same optimized
settings for Pb for our Sr measurements, and this should be appropriate for two reasons: 1)
the Sr binding energy is higher than Pb and we already have the maximum energy output
and filter combination to maximize the high energy x-ray spectrum, and minimize the
low energy part of the spectrum to the best of the current devices capabilities; and 2) we
wanted to validate the study using in vivo data already produced from the Pb poisoned
pediatric population assessed for Pb in chapter 3, which requires a calibration using the
same device settings used for the Pb measurements. Sr typically has a higher average
concentration in bone, which should make measurement easier.
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4.2.3

Spectrum Analysis

The spectra were analyzed using traditional peak fitting as for Pb measurements for this
population in chapter 3. The traditional peak fittings method is described in detail in
chapter 2. The analysis used a Gaussian with an exponential background to estimate net
counts. Then we used the Compton scattering peak to estimate soft-tissue thickness,
which was found from a calibration line based on soft tissue thickness. The soft tissue
thickness could then be used to identify the relationship between soft tissue corrected net
counts and concentration. With this process we used the peak energy of Sr at 14.2 keV
instead of Pb peak energies. The other Sr peak at 15.8 keV has a significant amount of
background from the characteristic x-rays produced by the Ag target in the x-ray tube that
underwent Compton scattering in the sample. The 15.8 keV peak also only represent 14%
of the total characteristic production with the majority being from the 14.2 keV peak.
Thus 14.2 keV was the only peak we used in our analysis procedures. Negative values for
bone Sr are left as such because they represent the point estimate of bone Sr with
uncertainty in the measurement. If an individual measurement is close to zero then the
point estimate from that individual can be negative with the associated uncertainty.
Linear regressions were used to determine correlation values and levels of
significance of relationships between age, sex, and portable XRF bone Sr. The portable
XRF data was excluded if the measurement time was <2 minutes.
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4.3

Results

4.3.1 Bone Sr Calibration Curve

The portable XRF was calibrated for in vivo bone Sr measurement by measuring Sr
phantoms of varying concentration at different Lucite thicknesses. Figure 4.1 shows the
results of the calibration curve obtained at 0 mm Lucite thickness. Figure 4.2 shows the
calibration line for 0, 1, 3, 5, 7.5, and 9 mm of Lucite thickness. This demonstrates the
degradation of signal to background ratio with increasing Lucite or soft tissue thickness.
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Figure 4.1 Calibration Curve for Sr at 0 mm Lucite thickness.
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Figure 4.2 Calibration lines for Sr phantom measurements from 0 mm to 9 mm of Lucite
thickness.

4.3.2

Calibration Function for Measurement of Bone Sr at Different Soft Tissue
Thicknesses

The function in Figure 4.3 below shows the calibration of the net Sr counts change with
increasing Lucite or soft tissue thickness for our 274 ppm phantom. This relation takes
into account the attenuation of soft tissue and inverse square degradation of the signal as
shown from our previous work in chapter 2.
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Figure 4.3 Calibration function for Sr counts at different Lucite/soft tissue thicknesses
with 274 ppm phantom

4.3.3

Minimum Detection Limit for Portable XRF Bone Sr Measurements

The MDL was calculated by measuring our standard phantoms of varying concentrations
of Sr with different Lucite thicknesses and using the following equation:

!"# =

2 × !"#
!"#$%

, where BKG is the background under the 14.2 keV Sr peak estimated from our fitting
program and the slope is taken from the calibration curve of all 10 phantoms at a
particular Lucite thickness. The resultant MDL is displayed in Figure 4.4.
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Figure 4.4 Minimum detection limit change over increasing Lucite thickness.

4.3.4

Portable XRF In Vivo Bone Sr Measurements

Table 4.1 shows summary statistics for the population measured for in vivo bone Sr. The
average age of the children measured was 5.7 ± 3.1 years. The difference between male
and female subjects for average bone Sr level was found to be non-significant with a pvalue of 0.25.
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Table 4.1 Statistics of Bone Strontium and Age for the Population
Bone Strontium (ppm)
N

Average

Minimum

Maximum

Male
Female
Total

165
72
237

45.9
36.6
43.2

-30.4
-32.3
-32.3

347.6
248.6
347.6

Standard
Deviation
56.9
59.3
57.6

Age (yrs)
Age (M)
Age (F)

237
165
72

5.7
5.6
6.0

1.0
1.0
1.0

15.0
15.0
14.2

3.1
2.8
3.7

4.3.5

Correlations Between Bone Sr and Age

Figures 4.5, 4.6, and 4.7 show correlations of bone Sr concentrations with ages. Figures
4.5 and 4.6 show significant correlations between age and bone Sr for a combined group
and then just females respectively with p-value<0.05. Figure 4.7 shows a non-significant
correlation between age and bone Sr for males. The slope of the correlations
demonstrates the estimated accumulation of Sr in bone per year in ppm.
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Figure 4.5 Significant correlation between bone Sr and age with combined male and
female subjects.
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Figure 4.6 Significant correlation between bone Sr and age for female subjects only.
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Figure 4.7 Non-significant correlation between bone Sr and age for male subjects only.

4.3.6

Age and Sex Differences in Accumulation of Bone Sr

We then investigated differences when splitting age groups depending on an estimation
of puberty status. A previous study estimated the ages in which puberty began in males
and females as 8-14.9 and 9.7-14.1 respectively [74]. We separated our results into these
age groups and determined if there were further significant differences between these
groups. Table 4.2 summarized statistics for the separated groups. The female groups had
significant differences of average bone Sr between the age groups with p-value<0.01. The
male groups had a non-significant difference of average bone Sr level for the age groups,
but showed an increasing trend with p-value of 0.165.
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Table 4.2 Bone Sr differences with puberty age and sex.
Bone Sr (ppm)
Min
Max

N

Average

Female >8yrs
Female <8yrs

23
49

66.2
22.6

-10.3
-32.3

248.6
146.7

69.4
48.6

Male >9.7yrs

18

60.8

-17.7

144.0

55.6

Male <9.7yrs

147

44.1

-30.4

347.6

57.0

4.4

Standard
Deviation

Discussion and Conclusions

This chapter demonstrated the ability of a portable XRF for measurement of in vivo bone
Sr levels within a 2-minute measurement. The device was calibrated using standard Sr
phantoms and Lucite and used to measure bone Sr in a group of Pb poisoned children.
We found that Sr does accumulate in bone and bone Sr has a significant relation with age,
which indicates that bone may be a long-term storage site for Sr. Accumulation of bone
Sr can be accurately monitored with the portable XRF. This technique can then be used to
monitor health effects associated with Sr exposure as well as monitoring patients using Sr
supplementation to treat osteoporosis.
Our calibration line demonstrated the linearity of the device with respect to Sr
levels. The contamination of the phantoms was evenly distributed throughout the bone
matrix, and with this level of contamination our calibration line was accurate to the
amount of Sr added to our phantoms. The contamination did increase the uncertainty of
the bone Sr concentrations which results from the increased uncertainties of the
parameters for the calibration line we obtained using our phantoms. In the future, we can
improve upon this calibration by using standards with less contamination from Sr.
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The calibration lines at different Lucite thicknesses are useful to visually assess
the detection limit of the device. Our MDL was calculated using slope to demonstrate the
change in signal from one concentration to another. The slope in Figure 4.2 clearly
decreases as the Lucite thickness increases, and at a certain point will have a very limited
difference between each concentration. This helps to demonstrate the limitations of the
portable XRF.
We determined the background estimation from the peak fitting was the most
acceptable means to estimate the MDL in our case without the ability to produce a 0 ppm
phantom. This was done using the background estimation from the fitting procedure,
which produced an exponential function. We used the area under the exponential
corresponding to two sigma of the Sr peak to estimate the background level for a
particular measurement. The calculated MDL was at a level low enough to detect Sr in
most subjects with less than 5mm skin thickness, as the average bone Sr level was found
to be 43.2 ± 57.6 ppm. Soft tissue thickness does have a significant effect on the
detection limit as seen in Figure 4.4. The soft tissue thickness increases uncertainty in the
measurement by decreasing our signal to background ratio as shown in our calculation of
detection limit. This is where the negative values in our study arise, because bone Sr
levels close to zero with high uncertainty from soft tissue thickness have a greater
possibility to be negative. Children in general will have thicker overlying soft tissue than
adults, and will have higher uncertainty in their measurements.
The correlations with age likely reflect the natural development of the children’s
bones. There are several factors here that could affect the correlation. We did not have
any information on the Sr exposure for each subject, so the possibility of someone being
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more or less exposed could be involved. Since diet plays a role in Sr metabolism, it is
also probable that some of the children had a higher metabolism of Sr due to less vitamin
D and protein in their diets.
Studies from Popovic et al 2005 and Mostafaei et al 2015, on Pb and fluorine,
demonstrated that differences in bone metabolism between sexes could influence bone
metal concentrations [75, 76]. Our study demonstrates similar sex differences in
accumulation of bone Sr. The female subjects were more likely to accumulate Sr with age
than the male subjects. Both male and female subjects showed an increase in Sr after
puberty age; however, the male data showed a non-significant difference. We attribute
the non-significance seen in our male subjects to the fact that there were only 18 subjects
older than 9.7 years, and we think a noticeable difference would be identifiable in studies
with more subjects. Since this was an estimation of puberty status based on age, there
could be further limitations. A better group distinction could be made using a
questionnaire for puberty status. The female results, which were much more noticeable in
our subjects, could be an indication of the influence of estrogen versus testosterone on
bone metabolism. Steroids are responsible for the maintenance of bone growth and
density until menopause in women [77]. A better test for these differences would be to
compare the bone Sr accumulation with age before and after puberty age, but due to the
small sample size of older subjects, we were unable to do this type of analysis. A pilot
study in adults with wider age ranges would help to further illuminate the differences
seen in this study.
In conclusion, Sr in bone is a valid biomarker for Sr accumulation and can be
used to assess the effectiveness of treatments or health effects associated with Sr intake or
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exposure. Our data shows that the portable XRF can be used to measure Sr in bone and
accurately determine bone Sr concentration for most subjects with a 2-minute
measurement time. The results also suggest possible sex differences in accumulation and
metabolism of Sr in bone.
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CHAPTER 5. HIGH ENERGY X-RAY TUBE BASED XRF MEASUREMENT
SYSTEM FOR IN VIVO QUANTIFICATION OF PB AND OTHER METALS

5.1

Introduction

K-shell x-ray fluorescence (KXRF) bone Pb measurement systems have widely expanded
our knowledge of Pb and its health effects over the past few decades. The most advanced
system using Cd-109 and a cloverleaf detector geometry has a detection limit of 2-3 µg/g
bone mineral. The KXRF measurement system has had many upgrades over the years,
but overall remains the same with the same limitations in portability, lengthy
measurement times, and a radioisotope source. The KXRF measurement system uses
liquid nitrogen cooled high-purity germanium detectors, which make the system itself
very large, especially when including the amplifiers and computer system to take the
measurement. This presents a problem for populations without the ability to go to a
location for a measurement. A portable XRF system using an x-ray tube and Si drift
detector has overcome these disadvantages, but introduced problems for other potential
populations. The portable XRF has limitations with the detection limit increasing
dramatically with thicker soft tissue thicknesses. Advances in detector and x-ray tube
technology would allow for the combination of the advantages for both the KXRF and
portable XRF bone Pb measurement systems to be transferred to a device that excluded
the main disadvantages of both. Using an x-ray tube source and different detector
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material would allow a system to be on the portable scale, which opens the possibility of
measurement of at risk populations such as the elderly who are not easily accessible to a
stationary device. Then, using the high-energy x-rays for KXRF measurements eliminates
any issues with soft tissue thickness. X-ray tubes have the capabilities of producing highenergy spectra through the use of high Z materials, such as Uranium, as targets.
Alternative detector materials, such as Cadmium Zinc Telluride (CdZnTe) or Silicon (Si),
offer advantages of operation at room temperature with trade-offs in detector resolution
and efficiency. This chapter demonstrates how we used Monte Carlo simulations to
determine the feasibility of an in vivo portable x-ray tube based KXRF bone Pb
measurement system and find its estimated sensitivity in comparison to the current Cd109 based KXRF and portable XRF measurement systems.

5.2

5.2.1

Materials and Methods

Monte Carlo Simulations

The Monte Carlo simulation program, Monte Carlo N-Particle transport code (MCNP),
used in our study was developed by Los Alamos National Lab and distributed by the
Radiation Safety Information Computational Center. This software has recently been
updated to more accurately depict interactions at lower energies, using its default
database for interaction cross-sections. This includes Doppler interactions and all the
main interactions observed in XRF previously discussed in this dissertation. This gives us
the ability to simulate an x-ray tube source with electron to photon conversions in the
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target. MCNP has the ability to set unique materials, densities, geometries, and sources in
order to reproduce an experimental setup.
We first wanted to verify the ability to replicate experimental setups using MCNP,
and then we could use it to optimize system parameters in this study of a high-energy xray tube for XRF applications.

5.2.2

Validation of MCNP Using a Portable XRF Experimental Comparison

We first tested the abilities of MCNP to accurately reproduce an x-ray tube spectrum by
simulating the portable XRF device. This device should be a good validation for MCNP’s
ability to depict the electron photon conversions in an x-ray tube. We measured the x-ray
tube output using a high-purity germanium (HPGe) detector. To reduce dead time of the
detector, we placed the x-ray tube 10 cm away. We recreated this setup in MCNP. We
started with electrons hitting the x-ray Ag target and proceeding through the filters and
collimators inherent in the device. We also needed to take into account the attenuation of
the x-rays through air and the aluminum window of the HPGe detector before being
detected. By taking the experimental measurement and comparing it to our simulation
result by looking at spectral features we can validate the ability of MCNP to reproduce an
x-ray tube source. Successful validation of this comparison allows us to use MCNP in
other applications of x-ray tube simulations and reproduce potential experimental results
for x-ray tube systems.
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5.2.3

High-Energy X-ray Tube Based KXRF Measurement System

The x-ray tube based KXRF system we modeled had specifications chosen based on
simulation and calculations shown in the results section, and has geometry shown in
Figure 5.1 below. The system utilized a 90-degree geometry between the x-ray source
and detector. The x-ray tube had an accelerating voltage of 220 kV, a 0.56 mm
transmission Uranium target, and a 1 cm tungsten collimator. The target thickness was
modeled and found to maximize K-shell fluorescence from the Uranium target, while
minimizing the low energy bremsstrahlung interactions creating excess background in the
Pb peak areas and radiation dose. The detector was modeled as silicon, cadmium zinc
telluride (CdZnTe), and HPGe with 1 cm thickness and a 3.2 cm diameter. The leg was
modeled with tibia bone of diameter 1.3 cm based on data in ICRP 70, with soft tissue
with a radius of 50 mm and thickness of 4.8 mm at the thinnest point surrounding the
bone [49].
The leg was simulated with an approximate distribution where the thickness
increased around the leg with the thinnest portion at the shin as shown in Figure 5.1. The
geometry of the leg was optimized using a comparison of changing the thinnest soft
tissue from pointing towards the source to pointing towards the detector. Figure 5.1
shows the thinnest section of soft tissue being about halfway between source and detector.
This geometry is used as a conservative estimate of the tibia bone and soft tissue, as the
thinnest portion of soft tissue would be longer than we have shown in this simulation.
The tibia bone close to the surface of the leg is flatter with respect to the surface and has
a triangular prism shape, shown in Figure 5.2, rather than the cylinder depicted in our
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simulation shown in Figure 5.1. The tibia bone we simulated had a Pb concentration of
100 ppm, which would be used to compare signal between different materials and
experimental devices using standards of the same concentration.
Two separate simulations were performed: 1) to get the initial spectra of x-rays
from the x-ray tube source and 2) to simulate the XRF interaction in leg and collect signal
in the detectors. The results from the first simulation were used to create the x-ray source
in the second. This allowed us to get much better statistics on the final spectra collected
in the detectors. The final simulation used Si, Ge, and CdZnTe detectors separately to
demonstrate differences between them. The detectors were all modeled with the same
standard size of 3.2 cm diameter and 1 cm thickness to match the standard KXRF
detector [9].

Figure 5.1 Simulated KXRF setup with x-ray tube source and detector in 90 degree
geometry and bone shown in the ‘halfway’ geometry.
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Figure 5.2 Human cadaver tibia bone cross-section to demonstrate the actual shape of the
tibia bone with the arrow depicting the portion towards the surface of the shin.

5.2.4

Normalization of Simulation Data to Experimental Results

The normalization of the simulation data is critical to getting accurate results when
comparing with experimental data. For the validation section of this study, ideally one
would do an assessment of dose starting from a given number of electrons or amperes in
the x-ray tube, but given the amount of geometry variables and unknown area of beam
from the portable XRF x-ray tube, this was too difficult. Thus for this simulation we used
a ratio of low energy and high-energy spectral features to find a normalization factor. A
similar method is used in other studies using MCNP [78]. The main interest for our
simulation would be the shape of the spectral features, which would confirm the x-ray
production, filtration, and attenuation of the beam. These would be the key features
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needed to identify a good comparison between simulation and experiment for our further
tests.
In our simulation for the high-energy x-ray tube based KXRF system, the
normalization is easier. For this simulation, we can instead do a normalization to dose of
the Cd-109. We used dose normalization to compare our x-ray tube based XRF to Cd-109
based systems using a skin dose of 40mSv to a 1cm2 area as our limiting factor and target
for normalization since this is the dose associated with the peak activity source of a Cd109 based KXRF system. Normalizing our simulation to the same dose as with a Cd-109
KXRF measurement would then give an accurate comparison of the signal from Pb
collected by either system without accounting for detector resolution, resolving time, and
background. We did a dose simulation for our x-ray tube and found a skin dose of 9.8e13 Sv per particle. We then normalized our dose based on the number of particles it
would take in the x-ray tube to reach a skin dose of 40 mSv, and found we needed to use
4.1e10 particle in our simulation to reach this dose. The simulation gave us values for the
probability of any starting particle actually being absorbed in the detector, which varied
for each detector material around ~13%. We then had to correct for the 230 energy bins
we had been using. Finally we could multiply this number, which varied based on the
detector material around ~3e6, by the known probability distribution from the simulation
to get a final normalized spectrum.
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5.3

5.3.1

Results

Validation of MCNP Using Experimental and Simulation Comparison of the
Portable XRF

The Monte Carlo simulations gave us comparisons between simulated spectra and
experimental spectra, which can be seen normalized to the experimental spectrum in the
30 keV to 50 keV energy range in Figure 5.3 below. The agreement for the overall
spectrum comparison of the x-ray tube output was about what was expected. The
normalization shown in this has no relation to dose matching, but is solely based on area
to demonstrate the correct shape acquired by the simulation in this case. Figure 5.3
demonstrates some limitations in the simulation in reproducing the background at lower
energies. The mismatch in the Compton scattering peak from the Ag target comes from
the detector resolution, and other effects discussed later in this chapter.

101

135000
115000

Simulation

Counts

95000

5000

75000

4000

55000

2000
1000

35000

0
10

15000
-5000

Experiment

3000

0

12

5

14

10

16

18

15

20

20

25

30

Energy (keV)

35

40

45

50

Figure 5.3 Experimental versus simulation spectrum comparison for x-ray tube output
from portable XRF.

5.3.2

High-Energy X-ray Tube Target Optimization

Uranium and thorium were chosen as possible targets because of the energies of
characteristic x-ray production as well as being explicitly cited as target materials in
patents for high z target x-ray tubes [79]. A comparison of the energy of the characteristic
x-rays from these targets after undergoing Compton scattering at various angles is seen in
Tables 5.1 and 5.2 below. Table 5.3 shows the Pb characteristic x-ray energies.
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Table 5.1 Thorium target characteristic x-ray energies after undergoing Compton
scattering at various angles.
Thorium
Angle
75
90
105
120
135
150
165
180
Relative
Intensities

Scattered Energy (keV)
K-alpha1
K-alpha2
83.9
79.6
80.5
76.5
77.3
73.7
74.6
71.2
72.4
69.2
70.8
67.7
69.9
66.9
69.6
66.6
100
62

K-beta
91.3
87.3
83.6
80.4
77.9
76.0
74.9
74.6
36

Table 5.2 Uranium target characteristic x-ray energies after undergoing Compton
scattering at various angles.
Uranium
Angle
75
90
105
120
135
150
165
180
Relative
Intensities

Scattered Energy (keV)
K-alpha1
K-alpha2
86.2
83.4
82.6
80.0
79.3
76.9
76.5
74.2
74.2
72.1
72.5
70.5
71.5
69.5
71.1
69.2
100
62

K-beta
94.0
89.8
85.9
82.6
79.9
78.0
76.8
76.4
37

Table 5.3 Pb characteristic x-ray emission energies.
Pb
Energy (keV)
Relative
Intensities

K-alpha1
75.0
100

K-alpha2
72.8
62

K-beta
84.9
35
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From the comparison of this data, the target and detector source angle was chosen
to not conflict with characteristic Pb x-rays. Thus, a 90-degree geometry using a Uranium
target was chosen as the optimal setup for our simulation.
The next step was to optimize the target thickness. The optimization was done by
maximizing the x-rays with energy greater than the binding energy of Pb and minimizing
the radiation dose. This method incorporated a way to identify which x-rays created in
the tube would ultimately be useful versus the x-rays just increasing our dose without
further use. Since we are also using dose as a normalization factor, it is of the utmost
importance that we minimize it in the optimization process.
In doing this optimization, it was most useful to create functions to define the
results to get a more precise calculation for the optimized target thickness. Using a
simulation for about 5 varying target thicknesses we could actually form a function that
would define the relationship over target thicknesses about equal to those already
simulated. The functions found for this optimization are presented below in Figures 5.4
and 5.5.
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Figure 5.4 Radiation dose for an XRF measurement versus the thickness of the
Uranium target in centimeters.
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Figure 5.5 X-ray production with energy greater than 88 keV versus Uranium target
thickness in centimeters.

Finally, these functions were compared as a ratio. We used a ratio since both dose and
potential signal should linearly affect our final characteristic yield in our simulation. This
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ratio was then maximized to find the most potential signal versus the least radiation dose,
and the optimal target thickness was found to be 0.56 mm. A visual representation of this
is seen in Figure 5.6 below. The final optimized spectrum with 0.56 mm target thickness

Ratio of signal to radiation dose

is shown in Figure 5.7.
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Figure 5.6 Potential x-ray signal divided by radiation dose versus Uranium target
thickness in centimeters.
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Figure 5.7 Optimized spectrum obtained using the 0.56 mm Uranium target thickness.

5.3.3

High-Energy X-ray Tube Geometry Optimization

Using our uranium target with a 90-degree geometry, we wanted to determine which
setup of three would be most optimal for the source detector geometry: 1) thinnest skin at
the x-ray tube source, 2) thinnest skin halfway between source and detector, and 3)
thinnest skin at the detector. The comparison between these situations can be seen in
Table 5.4 as a percentage of the signal from the optimized geometry with the thinnest
skin at the detector. To further clarify this comparison Figures 5.8 and 5.9 show an
example of the geometry for thinnest skin at the source and detector respectively.
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Table 5.4 Detector geometry optimization in terms of the thinnest skin direction.
Source

Halfway

Detector

0.326

0.644

1.000

Figure 5.8 Example of geometry with thinnest skin at the x-ray tube source.
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Figure 5.9 Example of geometry with thinnest skin at the detector.

5.3.4

Comparison Between the High-Energy X-ray Tube KXRF and Cd-109 KXRF
Bone Pb Measurements

The results from the simulation are shown in Table 5.5 below. A sample spectrum as
taken from the CdZnTe detector with 100 ppm phantom is shown below in Figure 5.10.
The simulation signals are normalized to the skin dose for Cd-109 based KXRF systems.
The signal ratio (SR) is a ratio of the simulated signal versus Cd-109 experimental signal
and is calculated as follows:

!" =

!!!! + !!!!
!!!!" + !!!!"
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where !!!! and !!!! are the net signals from simulation of K beta and alpha peaks, and
!!!!" and !!!!" are the net signals from Cd-109 based KXRF of K beta and alpha
peaks. All signals are taken from measurements of simulated or experimental 100 ppm
phantoms.

Table 5.5 Dose normalized signal comparison and MDL estimate of materials for KXRF
x-ray tube system.

Pb K Beta Signal (counts)
Pb K Alpha Signal (counts)
MDL Estimate (µg/g bone mineral)

Si
31
162
82.61

CdZnTe
980
3406
3.64

Ge
800
3092
4.10

Cd-109
based
920
4400
3

Normalized Counts

1.4E+03
1.2E+03
1.0E+03
8.0E+02
6.0E+02
4.0E+02
2.0E+02
0.0E+00
0

0.02

0.04

0.06

0.08

0.1
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0.2

Energy (MeV)

Figure 5.10 Sample spectrum as taken from the CdZnTe detector simulation for the 100
ppm phantom.
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5.4

Discussion and Conclusions

The results from this study show that it is feasible to use an x-ray tube based KXRF
system. Although there would be many obstacles to overcome in comparison to the Cd109 based system in terms of signal degradation by using a different geometry, using a
different material detector with lesser detector resolution, and using a source that has
non-optimal properties for exciting Pb energies in materials. Even considering these
initial problems, the system would still be viable for measurement albeit with a detection
limit greater than current modern Cd-109 based systems. The system would also have
advantages of current portable XRF technology because it would not have the significant
issues with skin thickness degrading the measurement. Our study also shows the validity
of using MCNP for x-ray tube and XRF simulations through comparison with
experimental work.
MCNP simulations showed good agreement with experimental results from our
Ag target x-ray tube based system. The simulation matched the shape of the experimental
spectrum well, demonstrating its ability to accurately determine electron interactions in
the target and filters through attenuation and absorption; however, one thing the
simulation lacked was an appropriate amount of background in the low energy areas of
the spectrum. With underestimation of the background, it is difficult to do a calculation of
detection limit, since normally the background counts are an integral component in the
calculation. Hence, this study uses signal to do a comparison of detection limit, because
we do not know whether or not the background is accurate. The Ag characteristic peaks
also matched poorly. Visually this was mostly a result of detector resolution. Numerically,
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this was because of the way the experimental spectrum was measured. Since
characteristic production is isotropic and bremsstrahlung production is mostly in the
forward direction, there will be more of a dependency on distance from the target in the
x-ray tube for characteristic production. Thus, being 10 cm away from the x-ray tube for
our measurement of the spectra impacted the resultant comparison between the
characteristic yield in the target versus the bremsstrahlung production, which would be
mostly in the forward direction. When correcting the spectrum this way, the percent error
between the Ag characteristics peaks for simulation and experiment goes to 0.4%.
The target thickness was optimized using potential signal production and radiation
dose. The use of potential signal production rather than actual signal production was
chosen to minimize time for simulations and to minimize the effect of the differences
between the two simulations. The first simulation of x-ray production has a different
source definition than the second simulation used to determine signal production for our
in vivo measurement. If we were to use actual signal production we would be using both
simulations, but by using only the potential of signal production with x-rays of >88 keV
we only used the initial x-ray tube simulation. Doing this helped to minimize any
potential differences between the simulations.
The choice of geometry is different from traditional Cd-109 systems with a 180degree geometry. A 180-degree geometry has both the source and detector centered on
the tibia bone with least amount of soft tissue interference. The 90-degree geometry was
chosen to limit any interference with Compton scattering from the uranium target.
Uranium characteristic energies from the uranium target scattered at 180-degrees would
be the same energy of the K-alpha characteristic energies of Pb, so these two different

112
peaks would likely be indistinguishable. The uranium characteristic energies scattered at
90-degrees are 5 keV higher than Pb K-alpha energies The K-alpha Pb peaks will be the
main source of signal for determining Pb concentration. Peaks from scatter will surround
the K-beta energy peak, but that peak only has 35% intensity and will contribute much
less to overall signal than the alpha peaks.
Optimizing the in vivo measurement for 90-degree geometry is less
straightforward than for the 180-degree geometry on the Cd-109 system. There are three
different geometries we tested using the simulation. Each setup pointed the shin, or the
portion of the leg with least soft tissue over the tibia bone, in different directions: at the xray tube source, 45-degrees between source and detector, and at the detector. This
comparison determined the maximum signal to arise from the geometry pointing the
thinnest skin section towards the detector. Although my simulated geometry used a crude
ellipsoid for the skin thickness and a less accurate cylinder for the tibia bone, this is likely
a true observation. By aligning the thinnest skin thickness with the detector, you will
collect the most Pb signals. When the x-ray tube irradiates the leg, the energy of the beam
is high enough to penetrate through the surfaces and successfully ionize elements in the
bone to create the initial Pb signal. That creation of signal would then serve as a
secondary isotropic source in the bone of the leg, which would by definition of the
inverse square law, have most signal collection by placing the detector closest to the bone
where the source is located. Thus, the optimized geometry with the thinnest skin at the
detector is justified.
The 90-degree geometry should work in our favor in terms of background levels.
Background, which will primarily come from a photon undergoing multiple Compton

113
scattering interactions, should be minimized with a 90-degree geometry. Although, other
scattering angles will each contribute small amounts to the background, looking at the
Klein-Nishina formula reveals that the majority of scattering will be in the forward
direction of the x-ray tube. Since 90-degree Compton scatter interactions at the energies
of our x-ray tube would have the lowest cross-section of any angle, the background
would be minimized in our 90-degree geometry, which would help lower the detection
limit of the device, especially since our analysis assumes equivalent background between
the Cd-109 system and our high energy x-ray tube system. One of the main reasons 180degree geometries are used is for convenience. It is significantly more convenient to have
the source mounted on the front of the detector and prevents interaction between the two,
as well as helping to isolate the geometry, but the 90-degree geometry has the potential
for lower background and better detection limit. When moving towards experimental
designs, the isolation of a consistent geometry will be the utmost concern for this system.
The detection limit calculation is crude since it assumes background to be the
same as for a Cd-109 system. A calculation of the detection limit using standard methods
with our simulated background yields a detection limit result less than Cd-109 systems,
which is false. Our calculation yields a more conservative estimate. Although these
detection limit estimates are crude, they do give us insight into the difference the detector
materials will make in our proposed system. It is also important to keep in mind the
detectors may differ in size from the estimates used for the simulation, and these
simulations did not take into account dead time or detector resolution, which will be
another area where signal loss will occur. The silicon detector from our simulation is
larger than anything currently available and thus unrealistic for consideration, but helps
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to demonstrate the material differences in detectors contributing to the detection limit
changes. Overall an experimental comparison will likely vary from the results shown
here, which tried to take a conservative estimate for the detection limit, but the results
should be consistent in verifying the feasibility of the system.
Although simulations leave out certain challenges the experimental setup will face,
we believe these results demonstrate the feasibility of a KXRF x-ray tube based system
based on the signal and detection limit estimates. There are numerous advantages of a
KXRF system that is much more portable without the hindrance of liquid nitrogen
cooling, using an x-ray tube source without degradation or complicated licensing, and
using k-shell energies for Pb measurement.
MCNP has been shown to be a validated method in properly simulating x-ray tube
physics by producing spectra of the same quality as experimental x-ray tubes of the same
design. A high-energy x-ray tube based KXRF system using a transmission target made
of uranium, has the ability to measure Pb in bone samples with a detection limit similar to
second-generation radioisotope based KXRF bone Pb measurement systems. By using
the high-energy of KXRF we can avoid the substantial limitations of soft tissue thickness
that are prevalent in the portable XRF, but still maintain relative portability with an x-ray
tube source. Based on these findings, development of a portable x-ray tube based KXRF
system is feasible for in vivo measurement of bone Pb.
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CHAPTER 6. CONCLUSION

A portable XRF device for quantification of Pb and Sr in vivo was developed in
this work. The device was calibrated using standard phantoms and validated in lab using
samples of cadaver and goat bone. The detection limit of the device for Pb was found to
be less than 10 ppm for soft tissue thicknesses less than 5 mm, which is on par with
conventional KXRF devices in most labs. The correlation between our cloverleaf Cd-109
KXRF and portable XRF bone Pb measurements for in lab samples correlated well and
demonstrated the device capabilities for in vivo measurement.
The device was used in tandem with our cloverleaf Cd-109 KXRF for validation
and measurement of bone Pb in a Pb poisoned children study in Shanghai, China. The
device was shown to have difficulties with particular anatomical differences in the
developing bones of children, but still maintained a significant correlation with the Cd109 KXRF measurements. We found blood Pb to have a higher correlation value with our
Cd-109 KXRF bone Pb measurements, which we associated with higher bone turnover in
children. We found the children to store most of their body burden of Pb in their bone,
and bone Pb to be a good biomarker for exposure in children. We were able to measure
the half-life of Pb in blood in select cases for our study and calculated the half-life to be
10.45±11.71 days, which is significantly different from adult blood Pb half-life values.
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We found a trend of decreased bone Pb values after chelation therapy, but the difference
was non-significant, which may point towards the efficacy of chelation in removing the
body Pb burden located primarily in bone. Since total Pb body burden is centralized in
the bone and the half-life of Pb in blood for children is much shorter than adults we infer
that bone Pb is a much better marker for monitoring Pb exposure and determining
chelation efficacy in children.
We then calibrated the portable XRF for measurements of Sr in vivo. We
produced a set of standard Sr phantoms using a new technique with Mowial-88 and bone
meal, which produced phantoms we could use for calibration and MDL calculations
appropriately. We found the MDL for Sr measurements to be about 15 ppm at about 9
mm of soft tissue thickness, which would be detectable for most subjects. We used the
data collected in our study of Pb poisoned children to determine the Sr levels of these
children and found an average of 43.2 ± 57.6 ppm of bone Sr. We correlated these values
with age and found a significant relation in the whole group and females, but not in males.
We then separated the groups by puberty age to identify any changes that may occur due
to increased sex hormones and found significant differences in girls before and after
puberty age. During this study we found that the portable XRF was able to measure bone
Sr in vivo for most subjects and could be used clinically in determining the efficacy of Sr
supplementation or toxicity of Sr exposure.
We finally explored the feasibility of creating a high-energy x-ray tube based
KXRF bone Pb measurement system. We validated the use of MCNP for determination
of experimental x-ray tube output. We determined a uranium target to be the most
appropriate to measure Pb in vivo. We found an optimized uranium target thickness of
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0.56 mm by minimizing radiation dose and maximizing potential signal. We then
estimated the detection limit of our high-energy x-ray tube bone Pb measurement system
to be 3.6 ppm by comparing the signal collected in the cloverleaf Cd-109 KXRF system
for a 100 ppm phantom. We determined that the device would be feasible for bone Pb
measurement with a detection limit about equivalent to a second-generation Cd-109
KXRF system.
In the future, the portable XRF can be applied for use in identifying other metals
and tissues for in vivo measurement, such as Mn and Hg in toenail. The portable XRF
can be applied to studies of subjects exposed to multiple metals for identification of
synergistic health effects. The calibration of the portable XRF can be further optimized if
a relation between composition and density changes in bone and spectral features can be
identified and manipulated for use in our measurements. Further studies of Pb in children
can reveal more information on the biokinetic differences observed in our study and may
shed light on further differences between adults and children in this respect. The highenergy x-ray tube based KXRF measurement system can be developed for measurements
of Pb and other metals in vivo with potential to overcome disadvantages seen in both
portable XRF and KXRF systems.
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